JP7446282B2 - Prmt5阻害剤 - Google Patents
Prmt5阻害剤 Download PDFInfo
- Publication number
- JP7446282B2 JP7446282B2 JP2021506583A JP2021506583A JP7446282B2 JP 7446282 B2 JP7446282 B2 JP 7446282B2 JP 2021506583 A JP2021506583 A JP 2021506583A JP 2021506583 A JP2021506583 A JP 2021506583A JP 7446282 B2 JP7446282 B2 JP 7446282B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- methyl
- pyrrolo
- diol
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940125897 PRMT5 inhibitor Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 235
- 239000000203 mixture Substances 0.000 claims description 225
- -1 2 -cyclopropyl Chemical group 0.000 claims description 104
- 206010028980 Neoplasm Diseases 0.000 claims description 94
- 150000003839 salts Chemical class 0.000 claims description 88
- 201000011510 cancer Diseases 0.000 claims description 78
- 229910052736 halogen Inorganic materials 0.000 claims description 78
- 150000002367 halogens Chemical class 0.000 claims description 78
- 238000011282 treatment Methods 0.000 claims description 58
- 239000003814 drug Substances 0.000 claims description 48
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 14
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 14
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- CKKZPYGYLPGVCZ-VCFPWYINSA-N (1S,2R,3aR,4S,6aR)-4-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound C1=NC(=C2C(=N1)N(C=C2)[C@@H]1C[C@@H]2[C@@H](CC[C@@]2([C@H]1O)O)CC1=CC2=NC(N)=C(C=C2C=C1)F)C CKKZPYGYLPGVCZ-VCFPWYINSA-N 0.000 claims description 4
- SJHAFRIQEZSPKK-GGBOSGNCSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(4-amino-5-ethylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound CCC1=CN(C2=NC=NC(=C12)N)[C@H]3[C@@H]([C@]4(CC[C@@H]([C@H]4O3)OC5=CC6=NC(=C(C=C6C=C5)Br)N)O)O SJHAFRIQEZSPKK-GGBOSGNCSA-N 0.000 claims description 4
- ONOYQVIMZYYIOW-VAKZPMALSA-N (2R,3S,4R,5R)-2-[(2-amino-3-bromoquinolin-7-yl)oxymethyl]-5-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-3-methyloxolane-3,4-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)OC[C@H]1O[C@H]([C@@H]([C@@]1(O)C)O)N1C=CC2=C1N=CN=C2Cl ONOYQVIMZYYIOW-VAKZPMALSA-N 0.000 claims description 4
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 4
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 4
- 125000006519 CCH3 Chemical group 0.000 claims description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 3
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 3
- CIHZMQXVROUJML-GABIRTJKSA-N (1R,2S,3R,5S)-5-[2-(2-amino-3-bromoquinolin-7-yl)ethyl]-3-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-1,5-dimethylcyclopentane-1,2-diol Chemical compound C[C@@]1(C[C@H]([C@@H]([C@]1(C)O)O)N2C=CC3=C(N=CN=C32)N)CCC4=CC5=NC(=C(C=C5C=C4)Br)N CIHZMQXVROUJML-GABIRTJKSA-N 0.000 claims description 2
- DYDYNDGVSIQNKX-KSZLKVKMSA-N (1S,2R,3S,5R)-3-[2-(2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl)ethyl]-3-methyl-5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol Chemical compound CC1=C2C=CN(C2=NC=N1)[C@@H]3C[C@]([C@H]([C@H]3O)O)(C)CCC4=CC5=NC6=C(CCN6)C=C5C=C4 DYDYNDGVSIQNKX-KSZLKVKMSA-N 0.000 claims description 2
- MWTDVARBFKTABI-XBJMDHIQSA-N (1S,2R,3S,5R)-3-[2-(2-amino-3-bromoquinolin-7-yl)ethyl]-3-methyl-5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol Chemical compound CC1=C2C=CN(C2=NC=N1)[C@@H]3C[C@]([C@H]([C@H]3O)O)(C)CCC4=CC5=NC(=C(C=C5C=C4)Br)N MWTDVARBFKTABI-XBJMDHIQSA-N 0.000 claims description 2
- TYWVDVASSSOQLE-XQQXVUDOSA-N (1S,2R,3S,5R)-3-[2-(2-amino-3-bromoquinolin-7-yl)ethyl]-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-methylcyclopentane-1,2-diol Chemical compound C[C@]1(CCC2=CC=C3C=C(Br)C(N)=NC3=C2)C[C@H]([C@H](O)[C@@H]1O)N1C=CC2=C1N=CN=C2N TYWVDVASSSOQLE-XQQXVUDOSA-N 0.000 claims description 2
- CKKZPYGYLPGVCZ-RDFICPIJSA-N (1S,2R,3aR,4R,6aR)-4-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)C[C@@H]1[C@H]2C[C@H]([C@@H]([C@]2(CC1)O)O)N1C=CC2=C1N=CN=C2C CKKZPYGYLPGVCZ-RDFICPIJSA-N 0.000 claims description 2
- ZAJACGXZJMZOJG-IHTMZYJLSA-N (1S,2R,3aR,4S,6aR)-2-(4-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-4-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound C1C[C@]2([C@@H]([C@@H]1CC3=CC4=NC(=C(C=C4C=C3)F)N)C[C@H]([C@@H]2O)N5C=C(C6=C(N=CN=C65)N)F)O ZAJACGXZJMZOJG-IHTMZYJLSA-N 0.000 claims description 2
- BWLSFVJDHPVMOF-QRDIQWRPSA-N (1S,2R,3aR,4S,6aR)-4-[(2-amino-3,5-difluoroquinolin-7-yl)methyl]-2-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound CC1=CN(C2=NC=NC(=C12)N)[C@@H]3C[C@@H]4[C@@H](CC[C@@]4([C@H]3O)O)CC5=CC6=NC(=C(C=C6C(=C5)F)F)N BWLSFVJDHPVMOF-QRDIQWRPSA-N 0.000 claims description 2
- LGCLGCPVEMVVEE-BKALFXMLSA-N (1S,2R,3aR,4S,6aR)-4-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-amino-2-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound CC1=NC(=C2C=CN(C2=N1)[C@@H]3C[C@@H]4[C@@H](CC[C@@]4([C@H]3O)O)CC5=CC6=NC(=C(C=C6C=C5)Br)N)N LGCLGCPVEMVVEE-BKALFXMLSA-N 0.000 claims description 2
- WZWWRSSLAMZVII-VCFPWYINSA-N (1S,2R,3aR,4S,6aR)-4-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@H]1[C@H]2C[C@H]([C@@H]([C@]2(CC1)O)O)N1C=CC2=C1N=CN=C2C WZWWRSSLAMZVII-VCFPWYINSA-N 0.000 claims description 2
- WMCRXFUTDRKJOU-QRDIQWRPSA-N (1S,2R,3aR,4S,6aR)-4-[(2-amino-3-chloro-5-fluoroquinolin-7-yl)methyl]-2-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound CC1=CN(C2=NC=NC(=C12)N)[C@@H]3C[C@@H]4[C@@H](CC[C@@]4([C@H]3O)O)CC5=CC6=NC(=C(C=C6C(=C5)F)Cl)N WMCRXFUTDRKJOU-QRDIQWRPSA-N 0.000 claims description 2
- HWSRPPYBLWQVOB-IHTMZYJLSA-N (1S,2R,3aR,4S,6aR)-4-[(2-amino-3-chloroquinolin-7-yl)methyl]-2-(4-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound C1C[C@]2([C@@H]([C@@H]1CC3=CC4=NC(=C(C=C4C=C3)Cl)N)C[C@H]([C@@H]2O)N5C=C(C6=C(N=CN=C65)N)F)O HWSRPPYBLWQVOB-IHTMZYJLSA-N 0.000 claims description 2
- VAZROUDJDVKISQ-UJXXXPMXSA-N (1S,2R,3aR,4S,6aR)-4-[(2-amino-3-chloroquinolin-7-yl)methyl]-2-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound CC1=CN(C2=NC=NC(=C12)N)[C@@H]3C[C@@H]4[C@@H](CC[C@@]4([C@H]3O)O)CC5=CC6=NC(=C(C=C6C=C5)Cl)N VAZROUDJDVKISQ-UJXXXPMXSA-N 0.000 claims description 2
- FYCVYLOEKJISEW-VCFPWYINSA-N (1S,2R,3aR,4S,6aR)-4-[(2-amino-3-chloroquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)C[C@H]1[C@H]2C[C@H]([C@@H]([C@]2(CC1)O)O)N1C=CC2=C1N=CN=C2C FYCVYLOEKJISEW-VCFPWYINSA-N 0.000 claims description 2
- JHJQPAFXPYGBCF-BKALFXMLSA-N (1S,2R,3aR,4S,6aR)-4-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2-(4-amino-2-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound NC=1C2=C(N=C(N=1)C)N(C=C2)[C@H]1[C@@H]([C@]2(CC[C@H]([C@H]2C1)CC1=CC=C2C=C(C(=NC2=C1)N)F)O)O JHJQPAFXPYGBCF-BKALFXMLSA-N 0.000 claims description 2
- HILIYWFGCWPGAC-UJXXXPMXSA-N (1S,2R,3aR,4S,6aR)-4-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,3a,4,5,6-hexahydro-1H-pentalene-1,6a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)C[C@H]1[C@H]2C[C@H]([C@@H]([C@]2(CC1)O)O)N1C=C(C2=C1N=CN=C2N)C HILIYWFGCWPGAC-UJXXXPMXSA-N 0.000 claims description 2
- LVBAWLSLFLNNPF-XGHJYUFYSA-N (2R,3R,3aS,5S,6S,6aR)-2-(4-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-5-fluoro-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound C1[C@@H]([C@H]([C@@H]2[C@]1([C@H]([C@@H](O2)N3C=C(C4=C(N=CN=C43)N)F)O)O)CC5=CC6=NC(=C(C=C6C=C5)F)N)F LVBAWLSLFLNNPF-XGHJYUFYSA-N 0.000 claims description 2
- GNFKTHAFMDHDKW-MYLPSIPISA-N (2R,3R,3aS,5S,6S,6aR)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-fluoro-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound C1[C@@H]([C@H]([C@@H]2[C@]1([C@H]([C@@H](O2)N3C=CC4=C(N=CN=C43)N)O)O)CC5=CC6=NC(=C(C=C6C=C5)F)N)F GNFKTHAFMDHDKW-MYLPSIPISA-N 0.000 claims description 2
- IXRBJOUYPQNPBC-LYHQQNOOSA-N (2R,3R,3aS,6R,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O IXRBJOUYPQNPBC-LYHQQNOOSA-N 0.000 claims description 2
- VCECDMPBGSDIQI-LYHQQNOOSA-N (2R,3R,3aS,6R,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-3,4,6,6a-tetrahydro-2H-furo[3,4-b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@H]1OC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O VCECDMPBGSDIQI-LYHQQNOOSA-N 0.000 claims description 2
- ZUFZAAGIXIUNOA-OHLFMSMFSA-N (2R,3R,3aS,6R,6aR)-6-[(2-amino-3-chloroquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)C[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O ZUFZAAGIXIUNOA-OHLFMSMFSA-N 0.000 claims description 2
- IJSSEGQOTZFHOF-DSCUAGCHSA-N (2R,3R,3aS,6S,6aR)-2-(4-amino-2-chloropyrrolo[2,3-d]pyrimidin-7-yl)-6-[(2-amino-3-chloroquinolin-7-yl)methyl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC=1C2=C(N=C(N=1)Cl)N(C=C2)[C@H]1[C@@H]([C@@]2([C@H](O1)[C@@H](CC2)CC1=CC=C2C=C(C(=NC2=C1)N)Cl)O)O IJSSEGQOTZFHOF-DSCUAGCHSA-N 0.000 claims description 2
- XQYOQXTYGUEHBQ-DSCUAGCHSA-N (2R,3R,3aS,6S,6aR)-2-(4-amino-2-chloropyrrolo[2,3-d]pyrimidin-7-yl)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC=1C2=C(N=C(N=1)Cl)N(C=C2)[C@H]1[C@@H]([C@@]2([C@H](O1)[C@@H](CC2)CC1=CC=C2C=C(C(=NC2=C1)N)F)O)O XQYOQXTYGUEHBQ-DSCUAGCHSA-N 0.000 claims description 2
- ASZVKSAYJJLCDA-DSCUAGCHSA-N (2R,3R,3aS,6S,6aR)-2-(4-amino-2-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC=1C2=C(N=C(N=1)F)N(C=C2)[C@H]1[C@@H]([C@@]2([C@H](O1)[C@@H](CC2)CC1=CC=C2C=C(C(=NC2=C1)N)F)O)O ASZVKSAYJJLCDA-DSCUAGCHSA-N 0.000 claims description 2
- GCIHVWJKUSRDLH-CDFBSHMBSA-N (2R,3R,3aS,6S,6aR)-2-(4-amino-5-cyclopropylpyrrolo[2,3-d]pyrimidin-7-yl)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound C1C[C@@]2([C@H]([C@@H](O[C@@H]2[C@@H]1CC3=CC4=NC(=C(C=C4C=C3)F)N)N5C=C(C6=C(N=CN=C65)N)C7CC7)O)O GCIHVWJKUSRDLH-CDFBSHMBSA-N 0.000 claims description 2
- NRWVGXVKZGAGRS-GECDNLLVSA-N (2R,3R,3aS,6S,6aR)-2-(4-amino-5-fluoro-2-methylpyrrolo[2,3-d]pyrimidin-7-yl)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=C(N=C2N)C)F)O NRWVGXVKZGAGRS-GECDNLLVSA-N 0.000 claims description 2
- QNWPDBGOZFHIPA-QRISMSBMSA-N (2R,3R,3aS,6S,6aR)-2-(4-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-6-(2-amino-3-fluoroquinolin-7-yl)oxy-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)F)O QNWPDBGOZFHIPA-QRISMSBMSA-N 0.000 claims description 2
- JDTALRZJCCAIMV-BDTSUPSPSA-N (2R,3R,3aS,6S,6aR)-2-(4-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)F)O JDTALRZJCCAIMV-BDTSUPSPSA-N 0.000 claims description 2
- USIBWHGYURISHY-RLYSOPCVSA-N (2R,3R,3aS,6S,6aR)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-6-(2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yloxy)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound C1C[C@@]2([C@H]([C@@H](O[C@@H]2[C@H]1OC3=CC4=NC5=C(CCN5)C=C4C=C3)N6C=CC7=C(N=CN=C76)N)O)O USIBWHGYURISHY-RLYSOPCVSA-N 0.000 claims description 2
- YSDUCWMCCDYQHY-UJLKNZRXSA-N (2R,3R,3aS,6S,6aR)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-6-[2-(2,2,2-trifluoroethylamino)quinolin-7-yl]oxy-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC=1C2=C(N=CN=1)N(C=C2)[C@H]1[C@@H]([C@@]2([C@H](O1)[C@H](CC2)OC1=CC=C2C=CC(=NC2=C1)NCC(F)(F)F)O)O YSDUCWMCCDYQHY-UJLKNZRXSA-N 0.000 claims description 2
- UULHAAMWYHLBAM-WFSJLAJTSA-N (2R,3R,3aS,6S,6aR)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-6-[2-(cyclopropylmethylamino)quinolin-7-yl]oxy-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC=1C2=C(N=CN=1)N(C=C2)[C@H]1[C@@H]([C@@]2([C@H](O1)[C@H](CC2)OC1=CC=C2C=CC(=NC2=C1)NCC1CC1)O)O UULHAAMWYHLBAM-WFSJLAJTSA-N 0.000 claims description 2
- NYCBPGXFVTWBEN-IPJNOFJESA-N (2R,3R,3aS,6S,6aR)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-6-[[2-amino-3-(trifluoromethyl)quinolin-7-yl]methyl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1C(F)(F)F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O NYCBPGXFVTWBEN-IPJNOFJESA-N 0.000 claims description 2
- ZMYUDLQOZFNPMT-PMJWCSBISA-N (2R,3R,3aS,6S,6aR)-6-(2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yloxy)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound N1CCC=2C1=NC1=CC(=CC=C1C=2)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O ZMYUDLQOZFNPMT-PMJWCSBISA-N 0.000 claims description 2
- LXQAKWPDCOXBFQ-OMDOPDFPSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(2,4-dimethylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=C(N=C2C)C)O LXQAKWPDCOXBFQ-OMDOPDFPSA-N 0.000 claims description 2
- OPTWFTFYVQBEGP-YZEAVIBISA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(2-amino-4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=C(N=C2C)N)O OPTWFTFYVQBEGP-YZEAVIBISA-N 0.000 claims description 2
- SDSZBZYVKGATFW-MNRGFROSSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(2-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=C(N=C2)N)F)O SDSZBZYVKGATFW-MNRGFROSSA-N 0.000 claims description 2
- FICIPFLSNLBOKF-ZQTGQNAUSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(2-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol dihydrochloride Chemical compound C1C[C@@]2([C@H]([C@@H](O[C@@H]2[C@H]1OC3=CC4=NC(=C(C=C4C=C3)Br)N)N5C=CC6=CN=C(N=C65)N)O)O.Cl.Cl FICIPFLSNLBOKF-ZQTGQNAUSA-N 0.000 claims description 2
- NYEHVKPEGVDNIG-BYYSDGHJSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(4-amino-2-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC=1C2=C(N=C(N=1)C)N(C=C2)[C@H]1[C@@H]([C@@]2([C@H](O1)[C@H](CC2)OC1=CC=C2C=C(C(=NC2=C1)N)Br)O)O NYEHVKPEGVDNIG-BYYSDGHJSA-N 0.000 claims description 2
- FICXCVPWYIKGGB-CRPWRWPOSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(4-amino-5-cyclopropylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)C1CC1)O FICXCVPWYIKGGB-CRPWRWPOSA-N 0.000 claims description 2
- KREZIUJANCEUQR-QRISMSBMSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(4-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)F)O KREZIUJANCEUQR-QRISMSBMSA-N 0.000 claims description 2
- ZKDNFRVRKGLRJQ-HCEATEFRSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound CC1=CN(C2=NC=NC(=C12)N)[C@H]3[C@@H]([C@]4(CC[C@@H]([C@H]4O3)OC5=CC6=NC(=C(C=C6C=C5)Br)N)O)O ZKDNFRVRKGLRJQ-HCEATEFRSA-N 0.000 claims description 2
- OGCPPNMJBHKXDD-GHCCLALKSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)C1=CC=CC=C1)O OGCPPNMJBHKXDD-GHCCLALKSA-N 0.000 claims description 2
- ZFKJNZBRQKSTDZ-OKLJIELZSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O ZFKJNZBRQKSTDZ-OKLJIELZSA-N 0.000 claims description 2
- IXRBJOUYPQNPBC-UYIBTEFRSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O IXRBJOUYPQNPBC-UYIBTEFRSA-N 0.000 claims description 2
- CLVVCVZSEYDAOB-DDNDUSOKSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-[4-(2-hydroxypropan-2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C(C)(C)O)O CLVVCVZSEYDAOB-DDNDUSOKSA-N 0.000 claims description 2
- ATAUGQUQYCXANM-HCEATEFRSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-[4-(difluoromethyl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C(F)F)O ATAUGQUQYCXANM-HCEATEFRSA-N 0.000 claims description 2
- MRIAFKDUEKKCEO-UYIBTEFRSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-[4-(hydroxymethyl)pyrrolo[2,3-d]pyrimidin-7-yl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2CO)O MRIAFKDUEKKCEO-UYIBTEFRSA-N 0.000 claims description 2
- YQIJJNQAUGANHO-JIGHVEHSSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-pyrrolo[2,3-d]pyrimidin-7-yl-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2)O YQIJJNQAUGANHO-JIGHVEHSSA-N 0.000 claims description 2
- OJKCVCRLBBKWCV-QRISMSBMSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-chloroquinolin-7-yl)oxy-2-(4-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)F)O OJKCVCRLBBKWCV-QRISMSBMSA-N 0.000 claims description 2
- XWENZSZFSCRRNQ-HCEATEFRSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-chloroquinolin-7-yl)oxy-2-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)C)O XWENZSZFSCRRNQ-HCEATEFRSA-N 0.000 claims description 2
- CLNRVOKXAUHYMB-OKLJIELZSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-chloroquinolin-7-yl)oxy-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O CLNRVOKXAUHYMB-OKLJIELZSA-N 0.000 claims description 2
- LSUJAZMWFUABKY-UYIBTEFRSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-chloroquinolin-7-yl)oxy-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O LSUJAZMWFUABKY-UYIBTEFRSA-N 0.000 claims description 2
- VGDZANFAHGXKPD-HCEATEFRSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-fluoroquinolin-7-yl)oxy-2-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound CC1=CN(C2=NC=NC(=C12)N)[C@H]3[C@@H]([C@]4(CC[C@@H]([C@H]4O3)OC5=CC6=NC(=C(C=C6C=C5)F)N)O)O VGDZANFAHGXKPD-HCEATEFRSA-N 0.000 claims description 2
- OPJSGLVCNKYGAA-OKLJIELZSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-fluoroquinolin-7-yl)oxy-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O OPJSGLVCNKYGAA-OKLJIELZSA-N 0.000 claims description 2
- UDEXVWVGLRAPQA-UYIBTEFRSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-fluoroquinolin-7-yl)oxy-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O UDEXVWVGLRAPQA-UYIBTEFRSA-N 0.000 claims description 2
- BGBRPMXAQDZVBJ-OBFXIHLUSA-N (2R,3R,3aS,6S,6aR)-6-(2-aminoquinolin-7-yl)oxy-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O BGBRPMXAQDZVBJ-OBFXIHLUSA-N 0.000 claims description 2
- CNVCEASFNDOXFB-LQLWBCBESA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3,5-difluoroquinolin-7-yl)methyl]-2-(4-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC(=C2C=C1F)F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)F)O CNVCEASFNDOXFB-LQLWBCBESA-N 0.000 claims description 2
- POWRCABYICIVSJ-JQWLKRHMSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3,5-difluoroquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC(=C2C=C1F)F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O POWRCABYICIVSJ-JQWLKRHMSA-N 0.000 claims description 2
- NVHMIRBTIAWSKH-LQLWBCBESA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3,6-difluoroquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=C(C=C2C=C1F)F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O NVHMIRBTIAWSKH-LQLWBCBESA-N 0.000 claims description 2
- HZDXICYPNYNSCT-BDTSUPSPSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3,8-difluoroquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=C(C(=CC=C2C=C1F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O)F HZDXICYPNYNSCT-BDTSUPSPSA-N 0.000 claims description 2
- NKTLGERVVYQQLE-SXEAMAFSSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(2,4-dimethylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=C(N=C2C)C)O NKTLGERVVYQQLE-SXEAMAFSSA-N 0.000 claims description 2
- WQGLSJXQMYHTTB-MBHBNJSUSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-amino-2-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC=1C2=C(N=C(N=1)C)N(C=C2)[C@H]1[C@@H]([C@@]2([C@H](O1)[C@@H](CC2)CC1=CC=C2C=C(C(=NC2=C1)N)Br)O)O WQGLSJXQMYHTTB-MBHBNJSUSA-N 0.000 claims description 2
- RSSGBUKTEASWGQ-BDTSUPSPSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)F)O RSSGBUKTEASWGQ-BDTSUPSPSA-N 0.000 claims description 2
- ZIWVFFNELCBPEP-MBHBNJSUSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)C)O ZIWVFFNELCBPEP-MBHBNJSUSA-N 0.000 claims description 2
- URPHSSFEIGYQFQ-HCEATEFRSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)-3,4,6,6a-tetrahydro-2H-furo[3,4-b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1OC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)C)O URPHSSFEIGYQFQ-HCEATEFRSA-N 0.000 claims description 2
- GFOGLQFOHVYPCS-IPJNOFJESA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O GFOGLQFOHVYPCS-IPJNOFJESA-N 0.000 claims description 2
- URRMKEZGOVGAJV-CSFAFAEBSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-cyclopropylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C1CC1)O URRMKEZGOVGAJV-CSFAFAEBSA-N 0.000 claims description 2
- CHFDOIQYYQBEKE-BNQFTCSMSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O CHFDOIQYYQBEKE-BNQFTCSMSA-N 0.000 claims description 2
- VCECDMPBGSDIQI-UYIBTEFRSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-3,4,6,6a-tetrahydro-2H-furo[3,4-b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1OC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O VCECDMPBGSDIQI-UYIBTEFRSA-N 0.000 claims description 2
- AZVDZIMIWQSRLE-CSFAFAEBSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(4-propan-2-ylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C(C)C)O AZVDZIMIWQSRLE-CSFAFAEBSA-N 0.000 claims description 2
- HKIFRDBEPOJOOQ-ATJWWJPSSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(5-fluoro-4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2C)F)O HKIFRDBEPOJOOQ-ATJWWJPSSA-N 0.000 claims description 2
- HUYMCCJYCOLZGR-MBHBNJSUSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-[4-(methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2NC)O HUYMCCJYCOLZGR-MBHBNJSUSA-N 0.000 claims description 2
- NLUUMMPZDGCADN-GECDNLLVSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-[5-fluoro-4-(methylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound CNC1=C2C(=CN(C2=NC=N1)[C@H]3[C@@H]([C@]4(CC[C@H]([C@H]4O3)CC5=CC6=NC(=C(C=C6C=C5)Br)N)O)O)F NLUUMMPZDGCADN-GECDNLLVSA-N 0.000 claims description 2
- ZKMJMERJMJJLKK-JQWLKRHMSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-chloro-5-fluoroquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC(=C2C=C1Cl)F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O ZKMJMERJMJJLKK-JQWLKRHMSA-N 0.000 claims description 2
- CWLZTITWJBGFGH-BDTSUPSPSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-chloro-8-fluoroquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=C(C(=CC=C2C=C1Cl)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O)F CWLZTITWJBGFGH-BDTSUPSPSA-N 0.000 claims description 2
- XQQIHCUYHPIWAT-ATJWWJPSSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-chloro-8-fluoroquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=C(C(=CC=C2C=C1Cl)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O)F XQQIHCUYHPIWAT-ATJWWJPSSA-N 0.000 claims description 2
- YLGPEPPSFBSNES-SXEAMAFSSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-chloroquinolin-7-yl)methyl]-2-(2,4-dimethylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=C(N=C2C)C)O YLGPEPPSFBSNES-SXEAMAFSSA-N 0.000 claims description 2
- GRIXXQVOHGGXHM-BDTSUPSPSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-chloroquinolin-7-yl)methyl]-2-(4-amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)F)O GRIXXQVOHGGXHM-BDTSUPSPSA-N 0.000 claims description 2
- RROUNUYFOLVKJM-MBHBNJSUSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-chloroquinolin-7-yl)methyl]-2-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=C(C2=C1N=CN=C2N)C)O RROUNUYFOLVKJM-MBHBNJSUSA-N 0.000 claims description 2
- CSWQYVVDDCLMFV-IPJNOFJESA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-chloroquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O CSWQYVVDDCLMFV-IPJNOFJESA-N 0.000 claims description 2
- ZUFZAAGIXIUNOA-BNQFTCSMSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-chloroquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O ZUFZAAGIXIUNOA-BNQFTCSMSA-N 0.000 claims description 2
- DAZSWKRGBDEBAF-UJLKNZRXSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-fluoroquinolin-7-yl)amino]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound CC1=C2C=CN(C2=NC=N1)[C@H]3[C@@H]([C@]4(CC[C@@H]([C@H]4O3)NC5=CC6=NC(=C(C=C6C=C5)F)N)O)O DAZSWKRGBDEBAF-UJLKNZRXSA-N 0.000 claims description 2
- KBSKIJGMWUHCDL-SXEAMAFSSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2-(2,4-dimethylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=C(N=C2C)C)O KBSKIJGMWUHCDL-SXEAMAFSSA-N 0.000 claims description 2
- YVTMLGNEXCKNHR-MBHBNJSUSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2-(4-amino-5-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound CC1=CN(C2=NC=NC(=C12)N)[C@H]3[C@@H]([C@]4(CC[C@H]([C@H]4O3)CC5=CC6=NC(=C(C=C6C=C5)F)N)O)O YVTMLGNEXCKNHR-MBHBNJSUSA-N 0.000 claims description 2
- SWEJAYJJBMNHQE-IPJNOFJESA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O SWEJAYJJBMNHQE-IPJNOFJESA-N 0.000 claims description 2
- PQPXDAZCKKYHAO-MEXCGKEESA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5,5-difluoro-3,4,6,6a-tetrahydro-2H-cyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)C[C@@H]1C(C[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O)(F)F PQPXDAZCKKYHAO-MEXCGKEESA-N 0.000 claims description 2
- KYCXNALLXVKWQW-WMGNBDEVSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-6a-methyl-3,4,5,6-tetrahydro-2H-cyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)C[C@@H]1CC[C@]2([C@@]1(O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)C)O KYCXNALLXVKWQW-WMGNBDEVSA-N 0.000 claims description 2
- KJAMXLPKMJCMAV-BNQFTCSMSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O KJAMXLPKMJCMAV-BNQFTCSMSA-N 0.000 claims description 2
- ULYIYZUQPCKZDI-BSYOGBIBSA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-methylquinolin-7-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1C)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O ULYIYZUQPCKZDI-BSYOGBIBSA-N 0.000 claims description 2
- GUOODKGCGPKLIS-XRIORSLDSA-N (2R,3R,3aS,6S,6aR)-6-[(6-amino-7-fluoro-1,5-naphthyridin-3-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound CC1=C2C=CN(C2=NC=N1)[C@H]3[C@@H]([C@]4(CC[C@H]([C@H]4O3)CC5=CC6=NC(=C(C=C6N=C5)F)N)O)O GUOODKGCGPKLIS-XRIORSLDSA-N 0.000 claims description 2
- NLCHGWMOWJVLRY-HAFCIWADSA-N (2R,3R,3aS,6S,6aR)-6-[(7-amino-6-chloro-1,8-naphthyridin-2-yl)methyl]-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound C1C[C@@]2([C@H]([C@@H](O[C@@H]2[C@@H]1CC3=NC4=NC(=C(C=C4C=C3)Cl)N)N5C=CC6=C(N=CN=C65)N)O)O NLCHGWMOWJVLRY-HAFCIWADSA-N 0.000 claims description 2
- HZRYIIHJFVZFKU-MOFNJSKZSA-N (2R,3R,3aS,6S,6aR)-6-[2-amino-3-(difluoromethyl)quinolin-7-yl]oxy-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1C(F)F)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O HZRYIIHJFVZFKU-MOFNJSKZSA-N 0.000 claims description 2
- GJEOEYYNMIPMTR-RLYSOPCVSA-N (2R,3R,3aS,6S,6aR)-6-[2-amino-3-(difluoromethyl)quinolin-7-yl]oxy-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1C(F)F)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O GJEOEYYNMIPMTR-RLYSOPCVSA-N 0.000 claims description 2
- LYYAIKFOTJLUDX-JYLDLCMYSA-N (2R,3R,3aS,6S,6aR)-6-[[2-amino-3-(difluoromethyl)quinolin-7-yl]methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1C(F)F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O LYYAIKFOTJLUDX-JYLDLCMYSA-N 0.000 claims description 2
- CGAWCYTWGHQGCW-BNQFTCSMSA-N (2R,3R,3aS,6S,6aR)-6-[[2-amino-3-(trifluoromethyl)quinolin-7-yl]methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1C(F)(F)F)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O CGAWCYTWGHQGCW-BNQFTCSMSA-N 0.000 claims description 2
- BOOAQGPBKIAJTB-VAKZPMALSA-N (2R,3S,4R,5R)-2-[(2-amino-3-bromoquinolin-7-yl)oxymethyl]-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2-methyloxolane-3,4-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)OC[C@]1(O[C@H]([C@@H]([C@@H]1O)O)N1C=CC2=C1N=CN=C2N)C BOOAQGPBKIAJTB-VAKZPMALSA-N 0.000 claims description 2
- HFCHCCQIGMRMOH-WOSNLTMFSA-N (2R,3S,4R,5R)-2-[(2-amino-3-bromoquinolin-7-yl)oxymethyl]-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyloxolane-3,4-diol Chemical compound [C@]1([C@@H](COC2=CC=C3C(N=C(C(=C3)Br)N)=C2)O[C@@H](N2C3=C(C=C2)C(N)=NC=N3)[C@@H]1O)(C#C)O HFCHCCQIGMRMOH-WOSNLTMFSA-N 0.000 claims description 2
- IGBXTOQFRZWGGX-WOSNLTMFSA-N (2R,3S,4R,5R)-2-[(2-amino-3-bromoquinolin-7-yl)oxymethyl]-5-(4-methoxypyrrolo[2,3-d]pyrimidin-7-yl)-2-methyloxolane-3,4-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)OC[C@]1(O[C@H]([C@@H]([C@@H]1O)O)N1C=CC2=C1N=CN=C2OC)C IGBXTOQFRZWGGX-WOSNLTMFSA-N 0.000 claims description 2
- HBUZOBRXQRUFEE-VAFVZNMKSA-N (2R,3S,4R,5R)-2-[2-(2-amino-3-bromoquinolin-7-yl)ethyl]-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dimethyloxolane-3,4-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)CC[C@]1(O[C@H]([C@@H]([C@@]1(O)C)O)N1C=CC2=C1N=CN=C2N)C HBUZOBRXQRUFEE-VAFVZNMKSA-N 0.000 claims description 2
- AARROQJKZRHUCI-RIRCHKGASA-N (5R,6S,6aS)-3-[(2-amino-3-bromoquinolin-7-yl)methyl]-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-1,3,3a,4,5,6-hexahydrocyclopenta[c]furan-6,6a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)CC1OC[C@]2(C1C[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2N)O AARROQJKZRHUCI-RIRCHKGASA-N 0.000 claims description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- NLCWLUOLBXOQFA-UJXXXPMXSA-N CC1=CN([C@H](C[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)Br)C3=C2)CC2)[C@]22O)[C@@H]2O)C2=C1C(N)=NC=N2 Chemical compound CC1=CN([C@H](C[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)Br)C3=C2)CC2)[C@]22O)[C@@H]2O)C2=C1C(N)=NC=N2 NLCWLUOLBXOQFA-UJXXXPMXSA-N 0.000 claims description 2
- GADPLURFYHCYGA-BKALFXMLSA-N CC1=NC(N([C@H](C[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)Cl)C3=C2)CC2)[C@]22O)[C@@H]2O)C=C2)=C2C(N)=N1 Chemical compound CC1=NC(N([C@H](C[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)Cl)C3=C2)CC2)[C@]22O)[C@@H]2O)C=C2)=C2C(N)=N1 GADPLURFYHCYGA-BKALFXMLSA-N 0.000 claims description 2
- WNCWSUKFAYASPC-MBHBNJSUSA-N CNC1=NC=NC2=C1C=CN2[C@@H]([C@@H]1O)O[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)F)C3=C2)CC2)[C@@]12O Chemical compound CNC1=NC=NC2=C1C=CN2[C@@H]([C@@H]1O)O[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)F)C3=C2)CC2)[C@@]12O WNCWSUKFAYASPC-MBHBNJSUSA-N 0.000 claims description 2
- LERDIBWXYUQECM-BKALFXMLSA-N CNC1=NC=NC2=C1C=CN2[C@H](C[C@H]([C@H](CC1=CC=C(C=C(C(N)=N2)Br)C2=C1)CC1)[C@]11O)[C@@H]1O Chemical compound CNC1=NC=NC2=C1C=CN2[C@H](C[C@H]([C@H](CC1=CC=C(C=C(C(N)=N2)Br)C2=C1)CC1)[C@]11O)[C@@H]1O LERDIBWXYUQECM-BKALFXMLSA-N 0.000 claims description 2
- IMWRYGDPIUOZJA-HRQSHJORSA-N C[C@@](COC1=CC=C(C=CC=N2)C2=C1)([C@H]([C@H]1O)O)O[C@H]1N(C=C1)C2=C1C(N)=NC=N2 Chemical compound C[C@@](COC1=CC=C(C=CC=N2)C2=C1)([C@H]([C@H]1O)O)O[C@H]1N(C=C1)C2=C1C(N)=NC=N2 IMWRYGDPIUOZJA-HRQSHJORSA-N 0.000 claims description 2
- QXZWQAVTCKOUGI-IJFYOMKJSA-N C[C@@]([C@@H](CCC1=CC=C(C=C(C(N)=N2)Br)C2=C1)C[C@H]1N(C=C2)C3=C2C(N)=NC=N3)([C@H]1O)O Chemical compound C[C@@]([C@@H](CCC1=CC=C(C=C(C(N)=N2)Br)C2=C1)C[C@H]1N(C=C2)C3=C2C(N)=NC=N3)([C@H]1O)O QXZWQAVTCKOUGI-IJFYOMKJSA-N 0.000 claims description 2
- QGLQEERHDRJERU-LDVYWZEYSA-N C[C@@]([C@@H](COC1=CC=C(C=C(C(N)=N2)Br)C2=C1)C[C@H]1N(C=C2)C3=C2C(Cl)=NC=N3)([C@H]1O)O Chemical compound C[C@@]([C@@H](COC1=CC=C(C=C(C(N)=N2)Br)C2=C1)C[C@H]1N(C=C2)C3=C2C(Cl)=NC=N3)([C@H]1O)O QGLQEERHDRJERU-LDVYWZEYSA-N 0.000 claims description 2
- KQGYGZMEMUWZEG-LDVYWZEYSA-N C[C@@]([C@@H](COC1=CC=C(C=C(C(N)=N2)Br)C2=C1)C[C@H]1N(C=C2)C3=C2C(N)=NC=N3)([C@H]1O)O Chemical compound C[C@@]([C@@H](COC1=CC=C(C=C(C(N)=N2)Br)C2=C1)C[C@H]1N(C=C2)C3=C2C(N)=NC=N3)([C@H]1O)O KQGYGZMEMUWZEG-LDVYWZEYSA-N 0.000 claims description 2
- GHDLMZCNEQIAOV-CMMZHZMSSA-N C[C@@]([C@@H](COC1=CC=C(C=C(C(N)=N2)Br)C2=C1)C[C@H]1N(C=C2)C3=C2C(NC)=NC=N3)([C@H]1O)O Chemical compound C[C@@]([C@@H](COC1=CC=C(C=C(C(N)=N2)Br)C2=C1)C[C@H]1N(C=C2)C3=C2C(NC)=NC=N3)([C@H]1O)O GHDLMZCNEQIAOV-CMMZHZMSSA-N 0.000 claims description 2
- XXNKAKLMXFOYKQ-SULFGKICSA-N C[C@@]([C@@H](COC1=CC=C(C=C(C)C(N)=N2)C2=C1)C[C@H]1N(C=C2)C3=C2C(C)=NC=N3)([C@H]1O)O Chemical compound C[C@@]([C@@H](COC1=CC=C(C=C(C)C(N)=N2)C2=C1)C[C@H]1N(C=C2)C3=C2C(C)=NC=N3)([C@H]1O)O XXNKAKLMXFOYKQ-SULFGKICSA-N 0.000 claims description 2
- SFJHXWHZFMHWKB-JXNRUCFJSA-N C[C@@]([C@@H](COC1=CC=C(C=CC(N)=N2)C2=C1)C[C@H]1N(C=C2)C3=C2C=NC=N3)([C@H]1O)O Chemical compound C[C@@]([C@@H](COC1=CC=C(C=CC(N)=N2)C2=C1)C[C@H]1N(C=C2)C3=C2C=NC=N3)([C@H]1O)O SFJHXWHZFMHWKB-JXNRUCFJSA-N 0.000 claims description 2
- WBNMIHYSSFNKKN-VWEIPLKFSA-N C[C@](CCC1=CC=C(C=C(CCN2)C2=N2)C2=C1)(C[C@H]([C@@H]1O)N(C=C2)C3=C2C(N)=NC=N3)[C@H]1O Chemical compound C[C@](CCC1=CC=C(C=C(CCN2)C2=N2)C2=C1)(C[C@H]([C@@H]1O)N(C=C2)C3=C2C(N)=NC=N3)[C@H]1O WBNMIHYSSFNKKN-VWEIPLKFSA-N 0.000 claims description 2
- KQGNWMQYRZPJRL-PGVBMLAISA-N C[C@](COC1=CC=C(C=CC(N)=N2)C2=C1)(C[C@H]([C@@H]1O)N(C=C2)C3=C2C(N)=NC=N3)[C@H]1O Chemical compound C[C@](COC1=CC=C(C=CC(N)=N2)C2=C1)(C[C@H]([C@@H]1O)N(C=C2)C3=C2C(N)=NC=N3)[C@H]1O KQGNWMQYRZPJRL-PGVBMLAISA-N 0.000 claims description 2
- CZKPNOKBCROSIV-BZDHPDOMSA-N C[C@]1(COc2ccc3cc(Br)c(N)nc3c2)C[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12 Chemical compound C[C@]1(COc2ccc3cc(Br)c(N)nc3c2)C[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12 CZKPNOKBCROSIV-BZDHPDOMSA-N 0.000 claims description 2
- UIUBZRZRNASGCO-QNLWLWTNSA-N NC1=NC2=CC(=CC=C2C=C1Br)CC[C@@]1([C@]([C@H]([C@@H](C1)N1C=CC2=C1N=CN=C2N)O)(O)C)O Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)CC[C@@]1([C@]([C@H]([C@@H](C1)N1C=CC2=C1N=CN=C2N)O)(O)C)O UIUBZRZRNASGCO-QNLWLWTNSA-N 0.000 claims description 2
- CUHBMWWZOQHSJP-CVXUCQRBSA-N NC1=NC2=CC(=CC=C2C=C1Br)C[C@H]1[C@H]2C[C@H]([C@@H]([C@]2(CC1)O)O)N1C=CC2=C1N=CN=C2N Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@H]1[C@H]2C[C@H]([C@@H]([C@]2(CC1)O)O)N1C=CC2=C1N=CN=C2N CUHBMWWZOQHSJP-CVXUCQRBSA-N 0.000 claims description 2
- WSQIJQSCLFECPV-GKAYAJSDSA-N NC1=NC2=CC(=CC=C2C=C1F)CC[C@]1([C@H]([C@H]([C@@H](C1)N1C=CC2=C1N=CN=C2N)O)O)C Chemical compound NC1=NC2=CC(=CC=C2C=C1F)CC[C@]1([C@H]([C@H]([C@@H](C1)N1C=CC2=C1N=CN=C2N)O)O)C WSQIJQSCLFECPV-GKAYAJSDSA-N 0.000 claims description 2
- NCOVDDLJQDCQEQ-QYYPHIJHSA-N NC1=NC=NC2=C1C(C(F)F)=CN2[C@@H]([C@@H]1O)O[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)Br)C3=C2)CC2)[C@@]12O Chemical compound NC1=NC=NC2=C1C(C(F)F)=CN2[C@@H]([C@@H]1O)O[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)Br)C3=C2)CC2)[C@@]12O NCOVDDLJQDCQEQ-QYYPHIJHSA-N 0.000 claims description 2
- OICCHAOELIQNMX-QYYPHIJHSA-N NC1=NC=NC2=C1C(C(F)F)=CN2[C@@H]([C@@H]1O)O[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)F)C3=C2)CC2)[C@@]12O Chemical compound NC1=NC=NC2=C1C(C(F)F)=CN2[C@@H]([C@@H]1O)O[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)F)C3=C2)CC2)[C@@]12O OICCHAOELIQNMX-QYYPHIJHSA-N 0.000 claims description 2
- IRBCOYJBTXINLA-IHTMZYJLSA-N NC1=NC=NC2=C1C(F)=CN2[C@H](C[C@H]([C@H](CC1=CC=C(C=C(C(N)=N2)Br)C2=C1)CC1)[C@]11O)[C@@H]1O Chemical compound NC1=NC=NC2=C1C(F)=CN2[C@H](C[C@H]([C@H](CC1=CC=C(C=C(C(N)=N2)Br)C2=C1)CC1)[C@]11O)[C@@H]1O IRBCOYJBTXINLA-IHTMZYJLSA-N 0.000 claims description 2
- JTNZGIBCTDMOMK-ZHUMNFKCSA-N NC1=NC=NC2=C1C=CN2[C@@H]([C@@H]1O)O[C@H]([C@H](CC2=CC=C(C=C(C(F)F)C(N)=N3)C3=C2)CC2)[C@@]12O Chemical compound NC1=NC=NC2=C1C=CN2[C@@H]([C@@H]1O)O[C@H]([C@H](CC2=CC=C(C=C(C(F)F)C(N)=N3)C3=C2)CC2)[C@@]12O JTNZGIBCTDMOMK-ZHUMNFKCSA-N 0.000 claims description 2
- GUBTWGLENJWADP-OKLJIELZSA-N NC1=NC=NC2=C1C=CN2[C@@H]([C@@H]1O)O[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)Br)C3=C2)OC2)[C@@]12O Chemical compound NC1=NC=NC2=C1C=CN2[C@@H]([C@@H]1O)O[C@H]([C@H](CC2=CC=C(C=C(C(N)=N3)Br)C3=C2)OC2)[C@@]12O GUBTWGLENJWADP-OKLJIELZSA-N 0.000 claims description 2
- OCYAISHYFQSCBD-KFMLXFHDSA-N NC1=NC=NC2=C1C=CN2[C@H](CC(CCC1=CC=C(C=C(C(N)=N2)Br)C2=C1)(CF)[C@H]1O)[C@@H]1O Chemical compound NC1=NC=NC2=C1C=CN2[C@H](CC(CCC1=CC=C(C=C(C(N)=N2)Br)C2=C1)(CF)[C@H]1O)[C@@H]1O OCYAISHYFQSCBD-KFMLXFHDSA-N 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- HSKVUWJDGRNZMI-UHFFFAOYSA-N OC(COC1CCC2)C12O Chemical compound OC(COC1CCC2)C12O HSKVUWJDGRNZMI-UHFFFAOYSA-N 0.000 claims 2
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 304
- 239000000243 solution Substances 0.000 description 143
- 235000019439 ethyl acetate Nutrition 0.000 description 136
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 131
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 129
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 111
- 230000002829 reductive effect Effects 0.000 description 108
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 91
- 239000012044 organic layer Substances 0.000 description 79
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 77
- 238000000034 method Methods 0.000 description 77
- 239000000543 intermediate Substances 0.000 description 70
- 238000006243 chemical reaction Methods 0.000 description 66
- 238000004440 column chromatography Methods 0.000 description 64
- 239000003112 inhibitor Substances 0.000 description 59
- 239000000377 silicon dioxide Substances 0.000 description 57
- 239000011541 reaction mixture Substances 0.000 description 56
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 52
- 239000003208 petroleum Substances 0.000 description 52
- 238000005481 NMR spectroscopy Methods 0.000 description 51
- 229920006395 saturated elastomer Polymers 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 47
- 239000003795 chemical substances by application Substances 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 239000000706 filtrate Substances 0.000 description 46
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 36
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 description 35
- 239000012267 brine Substances 0.000 description 35
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 35
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 31
- 239000012300 argon atmosphere Substances 0.000 description 31
- 238000003786 synthesis reaction Methods 0.000 description 31
- 239000011734 sodium Substances 0.000 description 28
- 125000005842 heteroatom Chemical group 0.000 description 27
- 239000002246 antineoplastic agent Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000000460 chlorine Substances 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 24
- 208000007056 sickle cell anemia Diseases 0.000 description 24
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 229940127089 cytotoxic agent Drugs 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 238000010898 silica gel chromatography Methods 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 16
- 238000010511 deprotection reaction Methods 0.000 description 16
- 238000010586 diagram Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 14
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 14
- NKLCNNUWBJBICK-UHFFFAOYSA-N DessMartin periodinane Substances C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 13
- 208000005980 beta thalassemia Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 208000034737 hemoglobinopathy Diseases 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 11
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 11
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 206010025323 Lymphomas Diseases 0.000 description 10
- 108010016731 PPAR gamma Proteins 0.000 description 10
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- 150000001336 alkenes Chemical class 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 10
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 229910021529 ammonia Inorganic materials 0.000 description 9
- 239000004037 angiogenesis inhibitor Substances 0.000 description 9
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 9
- 239000003886 aromatase inhibitor Substances 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 229940122361 Bisphosphonate Drugs 0.000 description 8
- 229940046844 aromatase inhibitors Drugs 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 150000004663 bisphosphonates Chemical class 0.000 description 8
- 150000002118 epoxides Chemical class 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000002834 estrogen receptor modulator Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 102000006495 integrins Human genes 0.000 description 8
- 108010044426 integrins Proteins 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 239000003558 transferase inhibitor Substances 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- 206010039491 Sarcoma Diseases 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 208000009956 adenocarcinoma Diseases 0.000 description 7
- 230000001028 anti-proliverative effect Effects 0.000 description 7
- 125000002619 bicyclic group Chemical group 0.000 description 7
- 230000012820 cell cycle checkpoint Effects 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 239000002254 cytotoxic agent Substances 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 102000027483 retinoid hormone receptors Human genes 0.000 description 7
- 108091008679 retinoid hormone receptors Proteins 0.000 description 7
- 239000000849 selective androgen receptor modulator Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 6
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 6
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- 108010069236 Goserelin Proteins 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 6
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 239000002111 antiemetic agent Substances 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 6
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000036457 multidrug resistance Effects 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 235000011121 sodium hydroxide Nutrition 0.000 description 6
- 239000012258 stirred mixture Substances 0.000 description 6
- 230000007755 survival signaling Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 5
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 102000014736 Notch Human genes 0.000 description 5
- 108010070047 Notch Receptors Proteins 0.000 description 5
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 5
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 5
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 5
- 230000003474 anti-emetic effect Effects 0.000 description 5
- 229940125683 antiemetic agent Drugs 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 5
- 239000004030 hiv protease inhibitor Substances 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 5
- 208000004235 neutropenia Diseases 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 5
- 229960005267 tositumomab Drugs 0.000 description 5
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 5
- HCRHJLIAWMTVIH-LOGJZDRZSA-N (1R,5R,8R,9R)-6-methoxy-3,3-dimethyl-2,4,7-trioxatricyclo[6.3.0.01,5]undecan-9-ol Chemical compound COC1O[C@H]2[C@]3(OC(O[C@H]31)(C)C)CC[C@H]2O HCRHJLIAWMTVIH-LOGJZDRZSA-N 0.000 description 4
- JIWHPAUZJQMSPT-JYYAWHABSA-N (1S,2R,6R,8S)-4,4-dimethyl-1-phenylmethoxy-3,5,7-trioxatricyclo[6.3.0.02,6]undecan-9-one Chemical compound O([C@]12CCC(=O)[C@H]1O[C@@H]1OC(O[C@@H]12)(C)C)CC1=CC=CC=C1 JIWHPAUZJQMSPT-JYYAWHABSA-N 0.000 description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 230000007067 DNA methylation Effects 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 4
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 4
- 102000006947 Histones Human genes 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102000010638 Kinesin Human genes 0.000 description 4
- 108010063296 Kinesin Proteins 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229940111134 coxibs Drugs 0.000 description 4
- 239000000824 cytostatic agent Substances 0.000 description 4
- 229960000975 daunorubicin Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 4
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 201000011066 hemangioma Diseases 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 229910052979 sodium sulfide Inorganic materials 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- QCIWZIYBBNEPKB-UHFFFAOYSA-N tert-butyl(dimethyl)silane Chemical compound C[SiH](C)C(C)(C)C QCIWZIYBBNEPKB-UHFFFAOYSA-N 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 4
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 3
- WKAIGFZWEJBZMN-CCFNYPOFSA-N (3R,3aS,6R,6aR)-2-methoxy-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a,6-triol Chemical compound COC1O[C@@H]2[C@H](O)CC[C@]2(O)[C@H]1O WKAIGFZWEJBZMN-CCFNYPOFSA-N 0.000 description 3
- UTTJNSGLORKNEQ-ZIKOTGLESA-N (3aR,5R,6R,6aR)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-6-ethenyl-2,2-dimethyl-6-phenylmethoxy-5,6a-dihydro-3aH-furo[2,3-d][1,3]dioxole Chemical compound CC1(C)OC[C@@H](O1)[C@H]1O[C@@H]2OC(C)(C)O[C@@H]2[C@@]1(OCc1ccccc1)C=C UTTJNSGLORKNEQ-ZIKOTGLESA-N 0.000 description 3
- KTZKPWSSHNQZKG-JYYAWHABSA-N (3ar,5s,6r,6ar)-6-ethenyl-2,2-dimethyl-6-phenylmethoxy-5,6a-dihydro-3ah-furo[2,3-d][1,3]dioxole-5-carbaldehyde Chemical compound O([C@]1(C=C)[C@@H](C=O)O[C@@H]2OC(O[C@@H]21)(C)C)CC1=CC=CC=C1 KTZKPWSSHNQZKG-JYYAWHABSA-N 0.000 description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 3
- OQJBFFCUFALWQL-BUHFOSPRSA-N (ne)-n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)\N=N\C(=O)N1CCCCC1 OQJBFFCUFALWQL-BUHFOSPRSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- QNOCLJTZVNFHLQ-UHFFFAOYSA-N 4-chloro-5-(difluoromethyl)-7H-pyrrolo[2,3-d]pyrimidine Chemical compound FC(F)c1c[nH]c2ncnc(Cl)c12 QNOCLJTZVNFHLQ-UHFFFAOYSA-N 0.000 description 3
- SZKMEPJJSHVYIC-UHFFFAOYSA-N 4-chloro-5-cyclopropyl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=2C(Cl)=NC=NC=2NC=C1C1CC1 SZKMEPJJSHVYIC-UHFFFAOYSA-N 0.000 description 3
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 3
- OUKVZDXSWJHLNI-UHFFFAOYSA-N 7-bromo-2-chloroquinoline-3-carbaldehyde Chemical compound BrC1=CC=C2C=C(C=O)C(Cl)=NC2=C1 OUKVZDXSWJHLNI-UHFFFAOYSA-N 0.000 description 3
- WIORTZMYDLZJIG-UHFFFAOYSA-N 7-bromo-3-fluoroquinolin-2-amine Chemical compound NC1=NC2=CC(Br)=CC=C2C=C1F WIORTZMYDLZJIG-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- UMPHMKSXKZIDTM-IXXDHKBRSA-N C(C1=CC=CC=C1)O[C@]12[C@H](OC([C@@H]1O)O)C(CC2)=C Chemical compound C(C1=CC=CC=C1)O[C@]12[C@H](OC([C@@H]1O)O)C(CC2)=C UMPHMKSXKZIDTM-IXXDHKBRSA-N 0.000 description 3
- VBABFXDNSBQFSD-RQJHMYQMSA-N CC(C)(C)OC(N([C@H](C[C@@H]12)C=C1Br)C2=O)=O Chemical compound CC(C)(C)OC(N([C@H](C[C@@H]12)C=C1Br)C2=O)=O VBABFXDNSBQFSD-RQJHMYQMSA-N 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 108010074604 Epoetin Alfa Proteins 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 108010029961 Filgrastim Proteins 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 102100025210 Histone-arginine methyltransferase CARM1 Human genes 0.000 description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
- 108010000817 Leuprolide Proteins 0.000 description 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 3
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 229960002932 anastrozole Drugs 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 229960002938 bexarotene Drugs 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960005243 carmustine Drugs 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 108010030886 coactivator-associated arginine methyltransferase 1 Proteins 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960000605 dexrazoxane Drugs 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 230000001973 epigenetic effect Effects 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 3
- 229960000255 exemestane Drugs 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- 229960002258 fulvestrant Drugs 0.000 description 3
- 101150034785 gamma gene Proteins 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 108060003196 globin Proteins 0.000 description 3
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 3
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 229940084651 iressa Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 229960003881 letrozole Drugs 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 231100000782 microtubule inhibitor Toxicity 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000006772 olefination reaction Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 3
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 3
- HVAMZGADVCBITI-UHFFFAOYSA-M pent-4-enoate Chemical compound [O-]C(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-M 0.000 description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 229960003171 plicamycin Drugs 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229960004622 raloxifene Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001718 repressive effect Effects 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 3
- 108010038379 sargramostim Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 229950001248 squalamine Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- ZNTBGAGWBNVSKG-IUCAKERBSA-N tert-butyl (1R,4S)-5-methyl-3-oxo-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate Chemical compound CC=1[C@H]2C(N([C@@H](C=1)C2)C(=O)OC(C)(C)C)=O ZNTBGAGWBNVSKG-IUCAKERBSA-N 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 3
- 229940099039 velcade Drugs 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- 229940033942 zoladex Drugs 0.000 description 3
- NTSGANFPVXLWIS-OUAUKWLOSA-N (1R)-1-[(2S,3R)-2-ethenyl-1,4-dioxaspiro[4.5]decan-3-yl]ethane-1,2-diol Chemical compound O1[C@@H](C=C)[C@@H]([C@H](O)CO)OC11CCCCC1 NTSGANFPVXLWIS-OUAUKWLOSA-N 0.000 description 2
- UXWVLWVKSLHKBT-JYYAWHABSA-N (1R,2R,6R,8R)-10,10-difluoro-4,4-dimethyl-9-methylidene-1-phenylmethoxy-3,5,7-trioxatricyclo[6.3.0.02,6]undecane Chemical compound CC1(O[C@H]2[C@@H](O1)O[C@H]3[C@@]2(CC(C3=C)(F)F)OCC4=CC=CC=C4)C UXWVLWVKSLHKBT-JYYAWHABSA-N 0.000 description 2
- JNRBTKDQUPWTBU-UHFFFAOYSA-N (2-amino-4-bromo-6-fluorophenyl)methanol Chemical compound NC1=C(C(=CC(=C1)Br)F)CO JNRBTKDQUPWTBU-UHFFFAOYSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- DPLMVEPCMWFNHU-VHSXEESVSA-N (2S,3S)-2-ethenyl-1,4-dioxaspiro[4.5]decane-3-carbaldehyde Chemical compound C=C[C@@H]1OC2(CCCCC2)O[C@@H]1C=O DPLMVEPCMWFNHU-VHSXEESVSA-N 0.000 description 2
- OBCZWRLNKFQOFN-VZTYQFELSA-N (3R,3aS,5S,6S)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-5-fluoro-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-2,3,3a-triol Chemical compound NC1=NC2=CC(=CC=C2C=C1F)C[C@@H]1[C@H](C[C@]2(C1OC([C@@H]2O)O)O)F OBCZWRLNKFQOFN-VZTYQFELSA-N 0.000 description 2
- VRJRINXDMKBJIK-KWLIJCASSA-N (3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-2,3,3a-triol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1OC([C@@H]2O)O)O VRJRINXDMKBJIK-KWLIJCASSA-N 0.000 description 2
- WKEFSIDTMRNTJY-LFLAVJEASA-N (3R,3aS,6S,6aR)-6-[(2-amino-3-fluoroquinolin-7-yl)methyl]-5,5-difluoro-3,4,6,6a-tetrahydro-2H-cyclopenta[b]furan-2,3,3a-triol Chemical compound C1[C@]2([C@@H]([C@@H](C1(F)F)CC3=CC4=NC(=C(C=C4C=C3)F)N)OC([C@@H]2O)O)O WKEFSIDTMRNTJY-LFLAVJEASA-N 0.000 description 2
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- MVGHBMROCDTNQP-UHFFFAOYSA-N 2-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)propan-2-ol Chemical compound N1C2=C(C=C1)C(C(C)(C)O)=NC=N2 MVGHBMROCDTNQP-UHFFFAOYSA-N 0.000 description 2
- XYUPZERKMMCICQ-UHFFFAOYSA-N 2-(difluoromethylsulfanyl)-1,3-benzothiazole Chemical compound C1=CC=C2SC(SC(F)F)=NC2=C1 XYUPZERKMMCICQ-UHFFFAOYSA-N 0.000 description 2
- SHKGYNFSRWBSDZ-UHFFFAOYSA-N 2-(difluoromethylsulfonyl)-1,3-benzothiazole Chemical compound C1=CC=C2SC(S(=O)(=O)C(F)F)=NC2=C1 SHKGYNFSRWBSDZ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- AVHZKSFWVOVKRZ-UHFFFAOYSA-N 2-amino-3-bromoquinolin-7-ol Chemical compound NC1=C(Br)C=C2C=CC(O)=CC2=N1 AVHZKSFWVOVKRZ-UHFFFAOYSA-N 0.000 description 2
- DVEPYWNSVJBFRR-UHFFFAOYSA-N 2-amino-4-bromo-6-fluorobenzaldehyde Chemical compound Nc1cc(Br)cc(F)c1C=O DVEPYWNSVJBFRR-UHFFFAOYSA-N 0.000 description 2
- GNFVFPBRMLIKIM-UHFFFAOYSA-N 2-fluoroacetonitrile Chemical compound FCC#N GNFVFPBRMLIKIM-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- AXRZNSAHAKTSOH-UTVKXTEFSA-N 3-bromo-7-[[(1R,5R,8R,9S)-6-methoxy-3,3-dimethyl-2,4,7-trioxatricyclo[6.3.0.01,5]undecan-9-yl]oxy]quinolin-2-amine Chemical compound BrC=1C(=NC2=CC(=CC=C2C=1)O[C@H]1CC[C@]23OC(O[C@H]2C(O[C@@H]31)OC)(C)C)N AXRZNSAHAKTSOH-UTVKXTEFSA-N 0.000 description 2
- QNZDXULJLFKFFB-RXGKKFSBSA-N 3-chloro-6-[[(1R,5R,8R,9S)-6-methoxy-3,3-dimethyl-2,4,7-trioxatricyclo[6.3.0.01,5]undecan-9-yl]methyl]quinolin-2-amine Chemical compound CC1(O[C@H]2C(O[C@H]3[C@]2(O1)CC[C@H]3CC4=CC5=CC(=C(N=C5C=C4)N)Cl)OC)C QNZDXULJLFKFFB-RXGKKFSBSA-N 0.000 description 2
- CBWBJFJMNBPWAL-UHFFFAOYSA-N 4-chloro-5-iodo-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(I)=CN2 CBWBJFJMNBPWAL-UHFFFAOYSA-N 0.000 description 2
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- SRKBPXNLGBUONZ-CXHZTBPHSA-N 7-[(1R,5R,6R,8R)-3,3-dimethyl-9-methylidene-2,4,7-trioxatricyclo[6.3.0.01,5]undecan-6-yl]-4-methylpyrrolo[2,3-d]pyrimidine Chemical compound CC1(O[C@@H]2[C@]3(O1)[C@H](O[C@H]2N1C=CC2=C1N=CN=C2C)C(CC3)=C)C SRKBPXNLGBUONZ-CXHZTBPHSA-N 0.000 description 2
- FSWWMLNGECQUNW-UHFFFAOYSA-N 7-bromo-2,3-dihydro-1h-pyrrolo[2,3-b]quinoline Chemical compound C1=C2CCNC2=NC2=CC(Br)=CC=C21 FSWWMLNGECQUNW-UHFFFAOYSA-N 0.000 description 2
- BEHCISYYWIFANN-UHFFFAOYSA-N 7-bromo-2-chloro-3-(difluoromethyl)quinoline Chemical compound BrC1=CC=C2C=C(C(=NC2=C1)Cl)C(F)F BEHCISYYWIFANN-UHFFFAOYSA-N 0.000 description 2
- JKKRDLBRVHUXMK-UHFFFAOYSA-N 7-bromo-3,5-difluoroquinolin-2-amine Chemical compound BrC1=CC(=C2C=C(C(=NC2=C1)N)F)F JKKRDLBRVHUXMK-UHFFFAOYSA-N 0.000 description 2
- NJWJZDHKLVDIJW-UHFFFAOYSA-N 7-bromo-3-(difluoromethyl)-N-[(4-methoxyphenyl)methyl]quinolin-2-amine Chemical compound BrC1=CC=C2C=C(C(=NC2=C1)NCC1=CC=C(C=C1)OC)C(F)F NJWJZDHKLVDIJW-UHFFFAOYSA-N 0.000 description 2
- WHTMYBPDZKQSCC-UHFFFAOYSA-N 7-bromo-3-(difluoromethyl)quinolin-2-amine Chemical compound BrC1=CC=C2C=C(C(=NC2=C1)N)C(F)F WHTMYBPDZKQSCC-UHFFFAOYSA-N 0.000 description 2
- MHRLNJUYFYVENE-UHFFFAOYSA-N 7-bromo-3-chloro-1,8-naphthyridin-2-amine Chemical compound BrC1=CC=C2C=C(C(=NC2=N1)N)Cl MHRLNJUYFYVENE-UHFFFAOYSA-N 0.000 description 2
- KSFQTOOWTKNZEL-UHFFFAOYSA-N 7-bromo-3-chloroquinolin-2-amine Chemical compound BrC1=CC=C2C=C(C(=NC2=C1)N)Cl KSFQTOOWTKNZEL-UHFFFAOYSA-N 0.000 description 2
- CWGPZBODFAUNQY-UHFFFAOYSA-N 7-bromo-3-fluoro-1,5-naphthyridin-2-amine Chemical compound BrC1=CN=C2C=C(C(=NC2=C1)N)F CWGPZBODFAUNQY-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- JHRCLADRFHZLGC-UHFFFAOYSA-N BrC1=CC=C2C=C(C(=NC2=C1F)N)Cl Chemical compound BrC1=CC=C2C=C(C(=NC2=C1F)N)Cl JHRCLADRFHZLGC-UHFFFAOYSA-N 0.000 description 2
- KXLZMRVGZLRCTA-HLYYOIJPSA-N C(C1=CC=CC=C1)O[C@@H]1CC[C@]2([C@@H]1OC([C@@H]2O)O)O Chemical compound C(C1=CC=CC=C1)O[C@@H]1CC[C@]2([C@@H]1OC([C@@H]2O)O)O KXLZMRVGZLRCTA-HLYYOIJPSA-N 0.000 description 2
- XREONAFIXOTSSM-CXXHRNMOSA-N C(C1=CC=CC=C1)O[C@@H]1CC[C@]23OC(O[C@H]2[C@@H](O[C@@H]31)N1C=CC2=C1N=CN=C2C)(C)C Chemical compound C(C1=CC=CC=C1)O[C@@H]1CC[C@]23OC(O[C@H]2[C@@H](O[C@@H]31)N1C=CC2=C1N=CN=C2C)(C)C XREONAFIXOTSSM-CXXHRNMOSA-N 0.000 description 2
- JCIVNYUVHHIPHG-UTUOFQBUSA-N C=C[C@H]([C@@H]1OC2(CCCCC2)O[C@@H]1C=C)O Chemical compound C=C[C@H]([C@@H]1OC2(CCCCC2)O[C@@H]1C=C)O JCIVNYUVHHIPHG-UTUOFQBUSA-N 0.000 description 2
- PIVJQRIEEJCYJV-UHFFFAOYSA-N CC(C)(C)OC(N(C(OC(C)(C)C)=O)C1=NC(N(C=C2)C(OC(C)(C)C)=O)=C2C=N1)=O Chemical compound CC(C)(C)OC(N(C(OC(C)(C)C)=O)C1=NC(N(C=C2)C(OC(C)(C)C)=O)=C2C=N1)=O PIVJQRIEEJCYJV-UHFFFAOYSA-N 0.000 description 2
- VRCMRLXDAWEGAL-CZTRHLISSA-N CC(C)(C)OC(N([C@H](C[C@H]1C2Br)C2[Se](C2=CC=CC=C2)=O)C1=O)=O Chemical compound CC(C)(C)OC(N([C@H](C[C@H]1C2Br)C2[Se](C2=CC=CC=C2)=O)C1=O)=O VRCMRLXDAWEGAL-CZTRHLISSA-N 0.000 description 2
- VVPXRJWSFJMNBG-HZLHGAJGSA-N CC(C)(C)OC(N([C@H](C[C@H]1[C@@]2(C)O)[C@@H]2O)C1=O)=O Chemical compound CC(C)(C)OC(N([C@H](C[C@H]1[C@@]2(C)O)[C@@H]2O)C1=O)=O VVPXRJWSFJMNBG-HZLHGAJGSA-N 0.000 description 2
- JJTFPHWDGBTSRE-VAOJYJGJSA-N CC(C)(O[C@@H]12)O[C@H]1O[C@H]([C@H](CC1=CC=C(C=C(C(N)=N3)F)C3=C1)[C@@H](C1)F)[C@@]21O Chemical compound CC(C)(O[C@@H]12)O[C@H]1O[C@H]([C@H](CC1=CC=C(C=C(C(N)=N3)F)C3=C1)[C@@H](C1)F)[C@@]21O JJTFPHWDGBTSRE-VAOJYJGJSA-N 0.000 description 2
- OMBYULWZLFVPAK-KXOGATPXSA-N CC(C)(O[C@H]12)O[C@@H]1[C@@](C)(COC1=CC=C(C=C(C(NCC(C=C3)=CC=C3OC)=N3)Br)C3=C1)O[C@H]2N(C=C1)C2=C1C(OC)=NC=N2 Chemical compound CC(C)(O[C@H]12)O[C@@H]1[C@@](C)(COC1=CC=C(C=C(C(NCC(C=C3)=CC=C3OC)=N3)Br)C3=C1)O[C@H]2N(C=C1)C2=C1C(OC)=NC=N2 OMBYULWZLFVPAK-KXOGATPXSA-N 0.000 description 2
- AXVXJCFNXGWQIF-XBCDXLOZSA-N CC(C)(O[C@H]12)O[C@]1(CCC1=C)[C@@H]1O[C@H]2N(C=C1C(F)F)C2=C1C(Cl)=NC=N2 Chemical compound CC(C)(O[C@H]12)O[C@]1(CCC1=C)[C@@H]1O[C@H]2N(C=C1C(F)F)C2=C1C(Cl)=NC=N2 AXVXJCFNXGWQIF-XBCDXLOZSA-N 0.000 description 2
- FFMIPQKAHQVOFH-DJZPMSPPSA-N CC1(O[C@@H]2[C@]3(O1)[C@H](O[C@H]2N1C=CC2=C1N=CN=C2N)C(CC3)=C)C Chemical compound CC1(O[C@@H]2[C@]3(O1)[C@H](O[C@H]2N1C=CC2=C1N=CN=C2N)C(CC3)=C)C FFMIPQKAHQVOFH-DJZPMSPPSA-N 0.000 description 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 2
- UJLJYLSZBANYBO-FCWDRERSSA-N C[C@@]([C@@H](CO)C[C@H]1N)([C@H]1O)O.Cl Chemical compound C[C@@]([C@@H](CO)C[C@H]1N)([C@H]1O)O.Cl UJLJYLSZBANYBO-FCWDRERSSA-N 0.000 description 2
- 101100326430 Caenorhabditis elegans bub-1 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DCHUHHXGELQWQZ-YJKIEOBBSA-N ClC=1C2=C(N=CN=1)N(C=C2)[C@@H]1O[C@@H]([C@@]2([C@H]1OC(O2)(C)C)C)CO Chemical compound ClC=1C2=C(N=CN=1)N(C=C2)[C@@H]1O[C@@H]([C@@]2([C@H]1OC(O2)(C)C)C)CO DCHUHHXGELQWQZ-YJKIEOBBSA-N 0.000 description 2
- DWFMWSSRYRWESE-DJZPMSPPSA-N ClC=1C2=C(N=CN=1)N(C=C2)[C@@H]1O[C@H]2[C@]3(OC(O[C@H]31)(C)C)CCC2=C Chemical compound ClC=1C2=C(N=CN=1)N(C=C2)[C@@H]1O[C@H]2[C@]3(OC(O[C@H]31)(C)C)CCC2=C DWFMWSSRYRWESE-DJZPMSPPSA-N 0.000 description 2
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 2
- 108010019673 Darbepoetin alfa Proteins 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 description 2
- 101000757216 Homo sapiens Protein arginine N-methyltransferase 1 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 102000017274 MDM4 Human genes 0.000 description 2
- 108050005300 MDM4 Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- JZXUWFPUMKZMTA-VAKZPMALSA-N NC1=NC2=CC(=CC=C2C=C1Br)OC[C@H]1O[C@H]([C@@H]([C@@]1(O)C)O)N1C=CC2=C1N=CN=C2N Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)OC[C@H]1O[C@H]([C@@H]([C@@]1(O)C)O)N1C=CC2=C1N=CN=C2N JZXUWFPUMKZMTA-VAKZPMALSA-N 0.000 description 2
- LMWGVOJNJIZWEJ-VNGNCMCHSA-N NC1=NC2=CC(=CC=C2C=C1Cl)C[C@@H]1CC[C@]2([C@@H]1OC([C@@H]2O)O)O Chemical compound NC1=NC2=CC(=CC=C2C=C1Cl)C[C@@H]1CC[C@]2([C@@H]1OC([C@@H]2O)O)O LMWGVOJNJIZWEJ-VNGNCMCHSA-N 0.000 description 2
- OBCZWRLNKFQOFN-ULCWDLOUSA-N NC1=NC2=CC(C[C@H]([C@@H](C[C@@]3([C@H]4O)O)F)[C@H]3OC4O)=CC=C2C=C1F Chemical compound NC1=NC2=CC(C[C@H]([C@@H](C[C@@]3([C@H]4O)O)F)[C@H]3OC4O)=CC=C2C=C1F OBCZWRLNKFQOFN-ULCWDLOUSA-N 0.000 description 2
- 229940123821 Neurokinin 1 receptor antagonist Drugs 0.000 description 2
- QSSYUVGWWQBOBQ-YXSASFKJSA-N OC144-093 Chemical compound CCO/C=C\CC(C=C1)=CC=C1C1=NC(C(C=C2)=CC=C2NC(C)C)=C(C(C=C2)=CC=C2NC(C)C)N1 QSSYUVGWWQBOBQ-YXSASFKJSA-N 0.000 description 2
- 229940049976 OC144-093 Drugs 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100022985 Protein arginine N-methyltransferase 1 Human genes 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- 241000720974 Protium Species 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- LGGHDPFKSSRQNS-UHFFFAOYSA-N Tariquidar Chemical compound C1=CC=CC2=CC(C(=O)NC3=CC(OC)=C(OC)C=C3C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CN=C21 LGGHDPFKSSRQNS-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229940123468 Transferase inhibitor Drugs 0.000 description 2
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- VDUIWEMUIJZDDJ-WMMRIRDVSA-N [(1R,5R,8R,9R)-6-methoxy-3,3-dimethyl-2,4,7-trioxatricyclo[6.3.0.01,5]undecan-9-yl] 4-methylbenzenesulfonate Chemical compound CC1=CC=C(C=C1)S(=O)(=O)O[C@@H]1CC[C@]23OC(O[C@H]2C(O[C@@H]31)OC)(C)C VDUIWEMUIJZDDJ-WMMRIRDVSA-N 0.000 description 2
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 2
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 229960001445 alitretinoin Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 238000007098 aminolysis reaction Methods 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 229960001830 amprenavir Drugs 0.000 description 2
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 229940087620 aromasin Drugs 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003719 aurora kinase inhibitor Substances 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- BKRKYEFQSANYGA-UHFFFAOYSA-N bromo-methyl-triphenyl-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Br)(C=1C=CC=CC=1)(C)C1=CC=CC=C1 BKRKYEFQSANYGA-UHFFFAOYSA-N 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 229940047495 celebrex Drugs 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229960005537 combretastatin A-4 Drugs 0.000 description 2
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000001672 cytoproliferative effect Effects 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 108010017271 denileukin diftitox Proteins 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960005215 dichloroacetic acid Drugs 0.000 description 2
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 2
- 208000024558 digestive system cancer Diseases 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229950004683 drostanolone propionate Drugs 0.000 description 2
- 229960003388 epoetin alfa Drugs 0.000 description 2
- 229930013356 epothilone Natural products 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 229940087861 faslodex Drugs 0.000 description 2
- 229940087476 femara Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 206010016629 fibroma Diseases 0.000 description 2
- 229960004177 filgrastim Drugs 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 229960004421 formestane Drugs 0.000 description 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003540 gamma secretase inhibitor Substances 0.000 description 2
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 229960003690 goserelin acetate Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 201000010235 heart cancer Diseases 0.000 description 2
- 208000024348 heart neoplasm Diseases 0.000 description 2
- QFXQOFFAIPZOSD-UHFFFAOYSA-N hept-1-en-6-yn-3-ol Chemical compound C=CC(O)CCC#C QFXQOFFAIPZOSD-UHFFFAOYSA-N 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- 229960003685 imatinib mesylate Drugs 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 2
- 229950006971 incadronic acid Drugs 0.000 description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
- 229960001936 indinavir Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960001614 levamisole Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- BCKCXCOIYQHPRK-UHFFFAOYSA-N n-(3-bromophenyl)-4-(1,3-dioxoisoindol-2-yl)butanamide Chemical compound BrC1=CC=CC(NC(=O)CCCN2C(C3=CC=CC=C3C2=O)=O)=C1 BCKCXCOIYQHPRK-UHFFFAOYSA-N 0.000 description 2
- PFPSZGPAQFBVHZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-[(4-phenyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide Chemical compound ClC1=CC=CC(NC(=O)CSC=2N(C(C=3C=CN=CC=3)=NN=2)C=2C=CC=CC=2)=C1 PFPSZGPAQFBVHZ-UHFFFAOYSA-N 0.000 description 2
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 2
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 2
- 229960000884 nelfinavir Drugs 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 201000011682 nervous system cancer Diseases 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- JIWAALDUIFCBLV-UHFFFAOYSA-N oxoosmium Chemical compound [Os]=O JIWAALDUIFCBLV-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 description 2
- 108010027841 pegademase bovine Proteins 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 2
- 229940043138 pentosan polysulfate Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 2
- 229960000952 pipobroman Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 229960001404 quinidine Drugs 0.000 description 2
- 108010077182 raf Kinases Proteins 0.000 description 2
- 102000009929 raf Kinases Human genes 0.000 description 2
- 108010084837 rasburicase Proteins 0.000 description 2
- 230000028617 response to DNA damage stimulus Effects 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 229960000371 rofecoxib Drugs 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- WRYSLFYACKIPNN-UHFFFAOYSA-M sodium;difluoromethanesulfinate Chemical compound [Na+].[O-]S(=O)C(F)F WRYSLFYACKIPNN-UHFFFAOYSA-M 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940120982 tarceva Drugs 0.000 description 2
- 229940099419 targretin Drugs 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- 229960000351 terfenadine Drugs 0.000 description 2
- NQIZWJGHIYDHRL-SFYZADRCSA-N tert-butyl (1s,4r)-2-oxo-3-azabicyclo[2.2.1]hept-5-ene-3-carboxylate Chemical compound C1[C@@]2([H])C=C[C@]1([H])N(C(=O)OC(C)(C)C)C2=O NQIZWJGHIYDHRL-SFYZADRCSA-N 0.000 description 2
- ZWVVTAQYQLDHLF-UHFFFAOYSA-N tert-butyl 2-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]-4-methylpyrrolo[2,3-d]pyrimidine-7-carboxylate Chemical compound C(C)(C)(C)OC(=O)N(C=1N=C(C2=C(N=1)N(C=C2)C(=O)OC(C)(C)C)C)C(=O)OC(C)(C)C ZWVVTAQYQLDHLF-UHFFFAOYSA-N 0.000 description 2
- XIGZOFXMTNMLAU-UHFFFAOYSA-N tert-butyl 7-bromo-2,3-dihydropyrrolo[2,3-b]quinoline-1-carboxylate Chemical compound BrC1=CC=C2C=C3C(=NC2=C1)N(CC3)C(=O)OC(C)(C)C XIGZOFXMTNMLAU-UHFFFAOYSA-N 0.000 description 2
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
- 229960005353 testolactone Drugs 0.000 description 2
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 2
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 2
- 229960000653 valrubicin Drugs 0.000 description 2
- 229950010938 valspodar Drugs 0.000 description 2
- 108010082372 valspodar Proteins 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- 229940002005 zometa Drugs 0.000 description 2
- 229950005752 zosuquidar Drugs 0.000 description 2
- IHOVFYSQUDPMCN-QKUIIBHLSA-N zosuquidar Chemical compound C([C@H](COC=1C2=CC=CN=C2C=CC=1)O)N(CC1)CCN1C1C2=CC=CC=C2C2C(F)(F)C2C2=CC=CC=C12 IHOVFYSQUDPMCN-QKUIIBHLSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- RIUGDBAWUIBLOQ-KYHPRHEASA-N (1R,2R,6R,8R)-4,4-dimethyl-9-methylidene-1-phenylmethoxy-3,5,7-trioxatricyclo[6.3.0.02,6]undecane Chemical compound C(C1=CC=CC=C1)O[C@]12[C@H](O[C@@H]3OC(O[C@@H]31)(C)C)C(CC2)=C RIUGDBAWUIBLOQ-KYHPRHEASA-N 0.000 description 1
- VTOQXZSJUZTLQD-XLKGFZLASA-N (1R,2R,6R,8R,10R)-10-fluoro-4,4-dimethyl-9-methylidene-1-phenylmethoxy-3,5,7-trioxatricyclo[6.3.0.02,6]undecane Chemical compound CC1(O[C@H]2[C@@H](O1)O[C@H]3[C@@]2(C[C@H](C3=C)F)OCC4=CC=CC=C4)C VTOQXZSJUZTLQD-XLKGFZLASA-N 0.000 description 1
- VTOQXZSJUZTLQD-IMSKVBIZSA-N (1R,2R,6R,8R,10S)-10-fluoro-4,4-dimethyl-9-methylidene-1-phenylmethoxy-3,5,7-trioxatricyclo[6.3.0.02,6]undecane Chemical compound CC1(O[C@H]2[C@@H](O1)O[C@H]3[C@@]2(C[C@@H](C3=C)F)OCC4=CC=CC=C4)C VTOQXZSJUZTLQD-IMSKVBIZSA-N 0.000 description 1
- DGYMNKOQEZGNIG-OWVAZHOYSA-N (1R,2R,6R,8R,9R)-4,4-dimethyl-1-phenylmethoxy-3,5,7-trioxatricyclo[6.3.0.02,6]undecan-9-ol Chemical compound O([C@]12CC[C@@H](O)[C@H]1O[C@@H]1OC(O[C@@H]12)(C)C)CC1=CC=CC=C1 DGYMNKOQEZGNIG-OWVAZHOYSA-N 0.000 description 1
- DJALDCPUPVLTGS-SQFXPHBZSA-N (1R,2S,3R,5R)-3-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-1-methylcyclopentane-1,2-diol Chemical compound C[C@]1([C@H](C[C@H]([C@@H]1O)N2C=CC3=C2N=CN=C3Cl)CO)O DJALDCPUPVLTGS-SQFXPHBZSA-N 0.000 description 1
- IDVMTOSHRPXHJR-HGKPHOSTSA-N (1R,5R,6R,8R,9R)-3,3-dimethyl-6-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,4,7-trioxatricyclo[6.3.0.01,5]undecan-9-ol Chemical compound CC1(O[C@@H]2[C@]3(O1)[C@H](O[C@H]2N1C=CC2=C1N=CN=C2C)[C@@H](CC3)O)C IDVMTOSHRPXHJR-HGKPHOSTSA-N 0.000 description 1
- ABYNARIMNGSPFJ-KAYRBKQESA-N (1R,5S,6R,8R,9S)-3,3-dimethyl-6-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,4-dioxatricyclo[6.3.0.01,5]undecan-9-ol Chemical compound CC1(O[C@]23[C@@H](O1)[C@@H](C[C@@H]3[C@H](CC2)O)N1C=CC2=C1N=CN=C2C)C ABYNARIMNGSPFJ-KAYRBKQESA-N 0.000 description 1
- DIXFPKPDGMBWJL-HLPPOEQASA-N (1S,2R,6R,8S)-10,10-difluoro-4,4-dimethyl-1-phenylmethoxy-3,5,7-trioxatricyclo[6.3.0.02,6]undecan-9-one Chemical compound CC1(O[C@H]2[C@@H](O1)O[C@H]3[C@@]2(CC(C3=O)(F)F)OCC4=CC=CC=C4)C DIXFPKPDGMBWJL-HLPPOEQASA-N 0.000 description 1
- UIXXDFDATMAIIM-UNKKGHFKSA-N (1S,2R,6R,8S)-10-fluoro-4,4-dimethyl-1-phenylmethoxy-3,5,7-trioxatricyclo[6.3.0.02,6]undecan-9-one Chemical compound CC1(O[C@H]2[C@@H](O1)O[C@H]3[C@@]2(CC(C3=O)F)OCC4=CC=CC=C4)C UIXXDFDATMAIIM-UNKKGHFKSA-N 0.000 description 1
- JKFZMIQMKFWJAY-RQJQXFIZSA-N (1r,3s,5z)-5-[(2e)-2-[(3as,7as)-1-[(2r)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC=C([C@]2(CCC1)C)[C@@H](CC#CC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C JKFZMIQMKFWJAY-RQJQXFIZSA-N 0.000 description 1
- DDUFYKNOXPZZIW-UHNVWZDZSA-N (1s,4r)-3-azabicyclo[2.2.1]hept-5-en-2-one Chemical compound C1[C@@H]2C(=O)N[C@H]1C=C2 DDUFYKNOXPZZIW-UHNVWZDZSA-N 0.000 description 1
- USYHIIHUJPBCQG-UHFFFAOYSA-N (2-chloroacetyl)-[5-methoxy-4-[2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl]carbamic acid Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(N(C(O)=O)C(=O)CCl)CCC21CO2 USYHIIHUJPBCQG-UHFFFAOYSA-N 0.000 description 1
- NFRYVRNCDXULEX-UHFFFAOYSA-N (2-diphenylphosphanylphenyl)-diphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C(=CC=CC=1)P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 NFRYVRNCDXULEX-UHFFFAOYSA-N 0.000 description 1
- YRQZONBVYBFPEX-UHFFFAOYSA-N (2-methylpropan-2-yl)oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[SiH](OC(C)(C)C)C1=CC=CC=C1 YRQZONBVYBFPEX-UHFFFAOYSA-N 0.000 description 1
- MDPMFOXROXYAFV-ZGMMZYFLSA-N (2R,3R,3aS,6S,6aR)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-6-(2-aminoquinolin-7-yl)oxy-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC=1C2=C(N=CN=1)N(C=C2)[C@H]1[C@@H]([C@@]2([C@H](O1)[C@H](CC2)OC1=CC=C2C=CC(=NC2=C1)N)O)O MDPMFOXROXYAFV-ZGMMZYFLSA-N 0.000 description 1
- LLDCTAVYVSMMBE-OKLJIELZSA-N (2R,3R,3aS,6S,6aR)-6-(2-amino-3-bromoquinolin-7-yl)oxy-2-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2Cl)O LLDCTAVYVSMMBE-OKLJIELZSA-N 0.000 description 1
- UIARQKZRDNZJQT-PGONPEIASA-N (2R,3R,3aS,6S,6aR)-6-[(2-amino-3-bromoquinolin-7-yl)methyl]-2-(2-amino-4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=C(N=C2C)N)O UIARQKZRDNZJQT-PGONPEIASA-N 0.000 description 1
- FVZMRHOWIQXBFP-RLZGZKAYSA-N (2R,3R,3aS,6S,6aR)-6-[(2-aminoquinolin-7-yl)methyl]-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-2,3,4,5,6,6a-hexahydrocyclopenta[b]furan-3,3a-diol Chemical compound NC1=NC2=CC(=CC=C2C=C1)C[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O FVZMRHOWIQXBFP-RLZGZKAYSA-N 0.000 description 1
- RWGYVJNNMMYWSZ-RZCHIYRCSA-N (2R,3R,3aS,6aR)-2-[4-chloro-5-(difluoromethyl)pyrrolo[2,3-d]pyrimidin-7-yl]-6-methylidene-3,4,5,6a-tetrahydro-2H-cyclopenta[b]furan-3,3a-diol Chemical compound C=C1[C@H]2O[C@@H](N3C4=C(C(=C3)C(F)F)C(Cl)=NC=N4)[C@@H]([C@]2(CC1)O)O RWGYVJNNMMYWSZ-RZCHIYRCSA-N 0.000 description 1
- BVKMMNVSRBLPDP-XJFOESAGSA-N (2R,3S,4R,5R)-5-(4-chloroindol-1-yl)-2-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound ClC1=C2C=CN(C2=CC=C1)[C@H]1[C@@H]([C@@]([C@H](O1)CO)(O)C)O BVKMMNVSRBLPDP-XJFOESAGSA-N 0.000 description 1
- PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 description 1
- OKUQEVHPQXKPCP-HHHXNRCGSA-N (2r)-7-[3-[2-chloro-4-(4-fluorophenoxy)phenoxy]propoxy]-2-ethyl-3,4-dihydrochromene-2-carboxylic acid Chemical compound C([C@](OC1=C2)(CC)C(O)=O)CC1=CC=C2OCCCOC(C(=C1)Cl)=CC=C1OC1=CC=C(F)C=C1 OKUQEVHPQXKPCP-HHHXNRCGSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- JTBVPIHWMWILJU-MHZLTWQESA-N (2s)-2-(2-acetylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid Chemical compound CC(=O)C1=CC=CC=C1N[C@H](C(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 JTBVPIHWMWILJU-MHZLTWQESA-N 0.000 description 1
- VGSJXSLGVQINOL-MHZLTWQESA-N (2s)-2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid Chemical compound C=1C=C(F)C=C(F)C=1NC(=O)N(CCCCCCC)CCC1=CC=C(O[C@@](C)(CC)C(O)=O)C=C1 VGSJXSLGVQINOL-MHZLTWQESA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- WMUIIGVAWPWQAW-DEOSSOPVSA-N (2s)-2-ethoxy-3-{4-[2-(10h-phenoxazin-10-yl)ethoxy]phenyl}propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OC2=CC=CC=C21 WMUIIGVAWPWQAW-DEOSSOPVSA-N 0.000 description 1
- MHFUWOIXNMZFIW-WNQIDUERSA-N (2s)-2-hydroxypropanoic acid;n-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound C[C@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 MHFUWOIXNMZFIW-WNQIDUERSA-N 0.000 description 1
- IRAAJHYKQDFNFO-SFHVURJKSA-N (2s)-3-[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoic acid Chemical compound N=1C2=CC=CC=C2OC=1N(C)CCOC1=CC=C(C[C@H](OCC(F)(F)F)C(O)=O)C=C1 IRAAJHYKQDFNFO-SFHVURJKSA-N 0.000 description 1
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2s,3r,4s,5s,6r)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- HQMOUBOMFSGBNR-BKVDRDDWSA-N (3aR,5R,6aR)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-6-ethenyl-2,2-dimethyl-5,6a-dihydro-3aH-furo[2,3-d][1,3]dioxol-6-ol Chemical compound CC1(OC[C@@H](O1)[C@@H]1C([C@@H]2[C@@H](OC(O2)(C)C)O1)(O)C=C)C HQMOUBOMFSGBNR-BKVDRDDWSA-N 0.000 description 1
- QSRFRZJIRAOQSJ-PEBGCTIMSA-N (3ar,5r,6as)-5-[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-3a,6a-dihydrofuro[2,3-d][1,3]dioxol-6-one Chemical compound O1C(C)(C)OC[C@@H]1[C@@H]1C(=O)[C@H]2OC(C)(C)O[C@H]2O1 QSRFRZJIRAOQSJ-PEBGCTIMSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- IXDZFGATLNCIOI-NGJCXOISSA-N (3r,4r,5r)-3,4,5,6-tetrahydroxyhexan-2-one Chemical class CC(=O)[C@H](O)[C@H](O)[C@H](O)CO IXDZFGATLNCIOI-NGJCXOISSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- ZKSNZYLCOXUJIR-VOKUKXJJSA-N (5s,5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7-(dimethylamino)-8-hydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)N(C)C)[C@@H]3[C@@H]2C(OC3)=O)=C1 ZKSNZYLCOXUJIR-VOKUKXJJSA-N 0.000 description 1
- DLROLUIVVKTFPW-LVEBQJTPSA-N (5s,5as,8ar,9r)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5-(4-nitroanilino)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](NC=3C=CC(=CC=3)[N+]([O-])=O)[C@@H]3[C@@H]2C(OC3)=O)=C1 DLROLUIVVKTFPW-LVEBQJTPSA-N 0.000 description 1
- UIARLYUEJFELEN-UHFFFAOYSA-N (5s,6s,8r)-6-hydroxy-6-(hydroxymethyl)-5-methyl-5,6,7,8,14,15-hexahydro-13h-5,8-epoxy-4b,8a,14-triazadibenzo[b,h]cycloocta[1,2,3,4-jkl]cyclopenta[e]-as-indacen-13-one Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1C1(C)C(CO)(O)CC4O1 UIARLYUEJFELEN-UHFFFAOYSA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- OPBPMGYBSDKJBT-DQHLZUIQSA-N (7s,9r,10r)-9-ethyl-4,6,9,10,11-pentahydroxy-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@]([C@@H](C3=C(O)C=4C(=O)C5=CC=CC(O)=C5C(=O)C=4C(O)=C32)O)(O)CC)CCOCC1 OPBPMGYBSDKJBT-DQHLZUIQSA-N 0.000 description 1
- BSRQHWFOFMAZRL-BODGVHBXSA-N (7s,9s)-7-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@@H](O)C[C@H](O[C@@H]2C3=C(O)C=4C(=O)C5=CC=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)O[C@H]1C BSRQHWFOFMAZRL-BODGVHBXSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 description 1
- QRPSQQUYPMFERG-LFYBBSHMSA-N (e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide Chemical compound ONC(=O)\C=C\C#CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 QRPSQQUYPMFERG-LFYBBSHMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- XGQXULJHBWKUJY-LYIKAWCPSA-N (z)-but-2-enedioic acid;n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound OC(=O)\C=C/C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C XGQXULJHBWKUJY-LYIKAWCPSA-N 0.000 description 1
- 150000000180 1,2-diols Chemical class 0.000 description 1
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- VDMKJSJJXQDICL-ZXVJYWQYSA-N 1,7-dipyridin-3-ylheptan-4-yl (2s)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O.COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2[C@@H](CCCC2)C(=O)OC(CCCC=2C=NC=CC=2)CCCC=2C=NC=CC=2)=C1 VDMKJSJJXQDICL-ZXVJYWQYSA-N 0.000 description 1
- VAMFSFIPDOODFH-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-(2,3-dihydro-1-benzofuran-5-ylsulfonyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(OCC2)C2=C1 VAMFSFIPDOODFH-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- QOVJBOKBPVDQHK-ZAKACXBJSA-N 1-[(3aR,5R,6R,6aR)-6-ethenyl-2,2-dimethyl-6-phenylmethoxy-5,6a-dihydro-3aH-furo[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol Chemical compound CC1(O[C@H]2[C@@H](O1)O[C@@H]([C@@]2(C=C)OCC3=CC=CC=C3)C(CO)O)C QOVJBOKBPVDQHK-ZAKACXBJSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- MZNMZWZGUGFQJP-UHFFFAOYSA-N 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(CCCCCCCCCC(O)CNCCCCCCCCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MZNMZWZGUGFQJP-UHFFFAOYSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- MUXBHXBDEFJJQK-UHFFFAOYSA-N 1-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCB1C2 MUXBHXBDEFJJQK-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- CVZBNRSGTBIHPO-UHFFFAOYSA-N 1-methylcyclopentane-1,2-diol Chemical compound CC1(O)CCCC1O CVZBNRSGTBIHPO-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- 125000003870 2-(1-piperidinyl)ethoxy group Chemical group [*]OC([H])([H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- XWNJMSJGJFSGRY-UHFFFAOYSA-N 2-(benzylamino)-3,7-dihydropurin-6-one Chemical compound N1C=2N=CNC=2C(=O)N=C1NCC1=CC=CC=C1 XWNJMSJGJFSGRY-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- XXGYVFAKVLKYMQ-UHFFFAOYSA-N 2-[(4-chloro-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)C=C(I)C2=C1Cl XXGYVFAKVLKYMQ-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- QUNOQBDEVTWCTA-UHFFFAOYSA-N 2-[2-[3-[2-(1,3-dioxobenzo[de]isoquinolin-2-yl)ethylamino]propylamino]ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)N(CCNCCCNCCN2C(C=3C=CC=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=CC=CC3=C1 QUNOQBDEVTWCTA-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- IEWQADGVLASNGW-UHFFFAOYSA-N 2-amino-4-bromo-3-fluorobenzaldehyde Chemical compound Nc1c(F)c(Br)ccc1C=O IEWQADGVLASNGW-UHFFFAOYSA-N 0.000 description 1
- PDUINDAMJWUPTI-UHFFFAOYSA-N 2-amino-6-bromopyridine-3-carbaldehyde Chemical compound NC1=NC(Br)=CC=C1C=O PDUINDAMJWUPTI-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 1
- BSWOAFDHSXXNQU-UHFFFAOYSA-N 2-chloro-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine Chemical compound ClC=1N=CC2=C(N=1)NC=C2F BSWOAFDHSXXNQU-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- ORVCATCRRUXRCE-UHFFFAOYSA-N 2-iodooxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OI ORVCATCRRUXRCE-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 1
- DJVCDUIKOLMZPB-UHFFFAOYSA-N 2H-cyclopenta[b]furan-3-ol Chemical compound C1=CC=C2OCC(O)=C21 DJVCDUIKOLMZPB-UHFFFAOYSA-N 0.000 description 1
- FFRFGVHNKJYNOV-DOVUUNBWSA-N 3',4'-Anhydrovinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C=C(C2)CC)N2CCC2=C1NC1=CC=CC=C21 FFRFGVHNKJYNOV-DOVUUNBWSA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- LBGAGUYLIVTKPI-UHFFFAOYSA-N 3-amino-5-bromopyridine-2-carbaldehyde Chemical compound NC1=CC(Br)=CN=C1C=O LBGAGUYLIVTKPI-UHFFFAOYSA-N 0.000 description 1
- CURYRIVJTBNEGU-UHFFFAOYSA-L 3-bromo-1-[12-(3-bromopropanoyl)-3,12-diaza-6,9-diazoniadispiro[5.2.5^{9}.2^{6}]hexadecan-3-yl]propan-1-one;dichloride Chemical compound [Cl-].[Cl-].C1CN(C(=O)CCBr)CC[N+]21CC[N+]1(CCN(CC1)C(=O)CCBr)CC2 CURYRIVJTBNEGU-UHFFFAOYSA-L 0.000 description 1
- AUHHINKFSCQZIT-UHFFFAOYSA-N 3-bromo-7-iodo-N-[(4-methoxyphenyl)methyl]quinolin-2-amine Chemical compound COC1=CC=C(CNC2=C(Br)C=C3C=CC(I)=CC3=N2)C=C1 AUHHINKFSCQZIT-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- FPCQTHLSVPIFQW-SIVSQDIGSA-N 3-fluoro-7-[[(1R,2R,6R,8R,9S,10S)-10-fluoro-4,4-dimethyl-1-phenylmethoxy-3,5,7-trioxatricyclo[6.3.0.02,6]undecan-9-yl]methyl]quinolin-2-amine Chemical compound CC1(O[C@H]2[C@@H](O1)O[C@H]3[C@@]2(C[C@@H]([C@H]3CC4=CC5=NC(=C(C=C5C=C4)F)N)F)OCC6=CC=CC=C6)C FPCQTHLSVPIFQW-SIVSQDIGSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- NXUNPWLNJCHHHM-UHFFFAOYSA-N 4,6-dichloro-5-(2,2-diethoxyethyl)pyrimidine Chemical compound CCOC(OCC)CC1=C(Cl)N=CN=C1Cl NXUNPWLNJCHHHM-UHFFFAOYSA-N 0.000 description 1
- HMKSXJBFBVGLJJ-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C(=O)N(CCCC(=O)O)C(=O)C2=C1 HMKSXJBFBVGLJJ-UHFFFAOYSA-N 0.000 description 1
- WIYNWLBOSGNXEH-UHFFFAOYSA-N 4-(2-amino-6,7-dimethoxyquinazolin-4-yl)phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC(N)=NC=1C1=CC=C(O)C=C1 WIYNWLBOSGNXEH-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- OZBUFFXESDBEHG-FXILSDISSA-N 4-[[(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OZBUFFXESDBEHG-FXILSDISSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- QOLJOOGZYMDOOO-UHFFFAOYSA-N 4-methyl-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound N1=C(N)NC2=NC=CC2=C1C QOLJOOGZYMDOOO-UHFFFAOYSA-N 0.000 description 1
- QWIAHMVNMONKCU-UHFFFAOYSA-N 4-methyl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CC1=NC=NC2=C1C=CN2 QWIAHMVNMONKCU-UHFFFAOYSA-N 0.000 description 1
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- WZXKBPYJTFTQAL-UHFFFAOYSA-N 5-methyl-n-[2-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound O1N=CC(C(=O)NC=2C(=CC=CC=2)C(F)(F)F)=C1C WZXKBPYJTFTQAL-UHFFFAOYSA-N 0.000 description 1
- GBOQUHPYCRYKGV-UHFFFAOYSA-N 5-nitro-2-(2-pyrrolidin-1-ylethyl)benzo[de]isoquinoline-1,3-dione Chemical compound O=C1C(C=23)=CC=CC3=CC([N+](=O)[O-])=CC=2C(=O)N1CCN1CCCC1 GBOQUHPYCRYKGV-UHFFFAOYSA-N 0.000 description 1
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- KAEVHZSIYLATMK-UHFFFAOYSA-N 6-n-[bis(aziridin-1-yl)phosphoryl]-2-n,2-n,7-trimethylpurine-2,6-diamine Chemical compound C=12N(C)C=NC2=NC(N(C)C)=NC=1NP(=O)(N1CC1)N1CC1 KAEVHZSIYLATMK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RGVRUQHYQSORBY-UHFFFAOYSA-N 7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyethyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(CCO)CC1OC1CC(N)C(O)C(C)O1 RGVRUQHYQSORBY-UHFFFAOYSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- YVVMIGRXQRPSIY-UHFFFAOYSA-N 7-deaza-2-aminopurine Chemical compound N1C(N)=NC=C2C=CN=C21 YVVMIGRXQRPSIY-UHFFFAOYSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-XMCQDBRXSA-N 7-hydroxystaurosporine Chemical compound N([C@@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@@H]1C[C@@H](NC)[C@@H](OC)[C@@]3(C)O1 PBCZSGKMGDDXIJ-XMCQDBRXSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 description 1
- 102000003989 Aurora kinases Human genes 0.000 description 1
- 108090000433 Aurora kinases Proteins 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010057654 Breast cancer female Diseases 0.000 description 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- ZXQOJJYRELNGMV-QIYLELGZSA-N C(C1=CC=CC=C1)O[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O Chemical compound C(C1=CC=CC=C1)O[C@@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2C)O ZXQOJJYRELNGMV-QIYLELGZSA-N 0.000 description 1
- VWFWICYTBONBPU-NLEAXPPASA-N C(C1=CC=CC=C1)O[C@]12[C@H](O[C@H]([C@@H]1O)N1C=CC3=C1N=CN=C3Cl)C(CC2)=C Chemical compound C(C1=CC=CC=C1)O[C@]12[C@H](O[C@H]([C@@H]1O)N1C=CC3=C1N=CN=C3Cl)C(CC2)=C VWFWICYTBONBPU-NLEAXPPASA-N 0.000 description 1
- MPLBQSAHVQXQPM-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=O)N(C2=O)CCC3=C(N=C4C=C(C=CC4=C3)Br)Cl Chemical compound C1=CC=C2C(=C1)C(=O)N(C2=O)CCC3=C(N=C4C=C(C=CC4=C3)Br)Cl MPLBQSAHVQXQPM-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- SXVRLNQTLMMPEG-DVRVPYBTSA-N C=C(CC[C@@]1([C@H]2O)OCC3=CC=CC=C3)[C@H]1O[C@H]2N(C=C1C(F)F)C2=C1C(Cl)=NC=N2 Chemical compound C=C(CC[C@@]1([C@H]2O)OCC3=CC=CC=C3)[C@H]1O[C@H]2N(C=C1C(F)F)C2=C1C(Cl)=NC=N2 SXVRLNQTLMMPEG-DVRVPYBTSA-N 0.000 description 1
- 125000006416 CBr Chemical group BrC* 0.000 description 1
- HLBZUXYNVUABFB-YYHMBLRTSA-N CC(C)(C)OC(N[C@H]1[C@@H]2OC(C)(C)O[C@]2(C)[C@@H](CO)C1)=O Chemical compound CC(C)(C)OC(N[C@H]1[C@@H]2OC(C)(C)O[C@]2(C)[C@@H](CO)C1)=O HLBZUXYNVUABFB-YYHMBLRTSA-N 0.000 description 1
- JQMYCAQFJQEDPC-DNNHASFKSA-N CC(C)(O[C@@H]12)O[C@H]1O[C@H]([C@H](CC1=CC=C(C=C(C(N)=N3)F)C3=C1)C(C1)(F)F)[C@@]21OCC1=CC=CC=C1 Chemical compound CC(C)(O[C@@H]12)O[C@H]1O[C@H]([C@H](CC1=CC=C(C=C(C(N)=N3)F)C3=C1)C(C1)(F)F)[C@@]21OCC1=CC=CC=C1 JQMYCAQFJQEDPC-DNNHASFKSA-N 0.000 description 1
- FPCQTHLSVPIFQW-WAHZKOFPSA-N CC(C)(O[C@@H]12)O[C@H]1O[C@H]([C@H](CC1=CC=C(C=C(C(N)=N3)F)C3=C1)[C@@H](C1)F)[C@@]21OCC1=CC=CC=C1 Chemical compound CC(C)(O[C@@H]12)O[C@H]1O[C@H]([C@H](CC1=CC=C(C=C(C(N)=N3)F)C3=C1)[C@@H](C1)F)[C@@]21OCC1=CC=CC=C1 FPCQTHLSVPIFQW-WAHZKOFPSA-N 0.000 description 1
- TZJUHXOMZDDPMT-IARIHHJXSA-N CC(C)(O[C@H]12)O[C@]1(CCC1=O)[C@@H]1O[C@H]2N(C=C1)C2=C1C(C)=NC=N2 Chemical compound CC(C)(O[C@H]12)O[C@]1(CCC1=O)[C@@H]1O[C@H]2N(C=C1)C2=C1C(C)=NC=N2 TZJUHXOMZDDPMT-IARIHHJXSA-N 0.000 description 1
- HXWQNAFVFGQIOR-KCYAQADSSA-N CC1(C)O[C@](CC[C@H]2OCC3=CC=CC=C3)([C@@H]2O[C@@H]2OC)[C@H]2O1 Chemical compound CC1(C)O[C@](CC[C@H]2OCC3=CC=CC=C3)([C@@H]2O[C@@H]2OC)[C@H]2O1 HXWQNAFVFGQIOR-KCYAQADSSA-N 0.000 description 1
- BZPWLMZAXBKYKU-SXRDFINZSA-N CCOC(CC(C(N[C@H](C[C@H](CO)[C@@]1(C)O)[C@@H]1O)=NC=N1)=C1Cl)OCC Chemical compound CCOC(CC(C(N[C@H](C[C@H](CO)[C@@]1(C)O)[C@@H]1O)=NC=N1)=C1Cl)OCC BZPWLMZAXBKYKU-SXRDFINZSA-N 0.000 description 1
- 108010082830 CEP 2563 Proteins 0.000 description 1
- 101150006084 CHKB gene Proteins 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- NAMMQHVAYDYBIJ-FKKSXTGDSA-N C[C@](COC1=CC=C(C=C(C(N)=N2)Br)C2=C1)(C[C@H]([C@@H]1O)N(C=C2)C3=C2C(N)=NC=N3)[C@@]1(C)O Chemical compound C[C@](COC1=CC=C(C=C(C(N)=N2)Br)C2=C1)(C[C@H]([C@@H]1O)N(C=C2)C3=C2C(N)=NC=N3)[C@@]1(C)O NAMMQHVAYDYBIJ-FKKSXTGDSA-N 0.000 description 1
- QJYSYYPARGTHQM-UHFFFAOYSA-N C[Si](C)(C)CCOCN(C=C1C2CC2)C2=C1C(Cl)=NC=N2 Chemical compound C[Si](C)(C)CCOCN(C=C1C2CC2)C2=C1C(Cl)=NC=N2 QJYSYYPARGTHQM-UHFFFAOYSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 102000003847 Carboxypeptidase B2 Human genes 0.000 description 1
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100025832 Centromere-associated protein E Human genes 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ZFDAVEIQHJEIOO-IWXIMVSXSA-N ClC=1C2=C(N=CN=1)N(C=C2)[C@H]1[C@@H]([C@@]([C@H](O1)CO)(O)C)O Chemical compound ClC=1C2=C(N=CN=1)N(C=C2)[C@H]1[C@@H]([C@@]([C@H](O1)CO)(O)C)O ZFDAVEIQHJEIOO-IWXIMVSXSA-N 0.000 description 1
- CCJAXXXBHNRVFF-PJQZNRQZSA-N ClC=1C2=C(N=CN=1)N(C=C2)[C@H]1[C@@H]([C@@]2([C@H](O1)C(CC2)=C)O)O Chemical compound ClC=1C2=C(N=CN=1)N(C=C2)[C@H]1[C@@H]([C@@]2([C@H](O1)C(CC2)=C)O)O CCJAXXXBHNRVFF-PJQZNRQZSA-N 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- RSCIYYHIBVZXDI-UHFFFAOYSA-O Fagaridine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(O)=C4C=[N+](C)C3=C21 RSCIYYHIBVZXDI-UHFFFAOYSA-O 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- CEVCTNCUIVEQOY-UHFFFAOYSA-N Fumagillol Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(O)CCC21CO2 CEVCTNCUIVEQOY-UHFFFAOYSA-N 0.000 description 1
- GGUVRMBIEPYOKL-WMVCGJOFSA-N GW 409544 Chemical compound C([C@H](NC(/C)=C\C(=O)C=1C=CC=CC=1)C(O)=O)C(C=C1)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 GGUVRMBIEPYOKL-WMVCGJOFSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102000007513 Hemoglobin A Human genes 0.000 description 1
- 108010085682 Hemoglobin A Proteins 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 101000924629 Homo sapiens Apoptotic protease-activating factor 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000605743 Homo sapiens Kinesin-like protein KIF23 Proteins 0.000 description 1
- 101100434930 Homo sapiens PRMT5 gene Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101000757232 Homo sapiens Protein arginine N-methyltransferase 2 Proteins 0.000 description 1
- 101000924530 Homo sapiens Protein arginine N-methyltransferase 5 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 101150026926 JBP1 gene Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 102100038406 Kinesin-like protein KIF23 Human genes 0.000 description 1
- 102100023424 Kinesin-like protein KIF2C Human genes 0.000 description 1
- 101710134369 Kinesin-like protein KIF2C Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 1
- DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- NQDQBAQSFQCDTF-UHFFFAOYSA-N N-(3-chlorophenyl)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine methanesulfonic acid Chemical compound CS(O)(=O)=O.Cc1[nH]c2ncnc(Nc3cccc(Cl)c3)c2c1C NQDQBAQSFQCDTF-UHFFFAOYSA-N 0.000 description 1
- GCIKSSRWRFVXBI-UHFFFAOYSA-N N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 GCIKSSRWRFVXBI-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- BTYYWOYVBXILOJ-UHFFFAOYSA-N N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide Chemical compound C12=CC(NC(=O)C#CC)=CC=C2N=CN=C1NC1=CC=CC(Br)=C1 BTYYWOYVBXILOJ-UHFFFAOYSA-N 0.000 description 1
- OOCLXDDUKLGFDC-BYYSDGHJSA-N NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2NC)O Chemical compound NC1=NC2=CC(=CC=C2C=C1Br)O[C@H]1CC[C@]2([C@@H]1O[C@H]([C@@H]2O)N1C=CC2=C1N=CN=C2NC)O OOCLXDDUKLGFDC-BYYSDGHJSA-N 0.000 description 1
- CRURQPFOCBAXHZ-XNNMGNNJSA-N NC1=NC=NC2=C1C=CN2[C@H](C[C@H]([C@H](CC1)OC2=CC=C(C=C(C(N)=N3)Br)C3=C2)[C@]11O)[C@@H]1O Chemical compound NC1=NC=NC2=C1C=CN2[C@H](C[C@H]([C@H](CC1)OC2=CC=C(C=C(C(N)=N3)Br)C3=C2)[C@]11O)[C@@H]1O CRURQPFOCBAXHZ-XNNMGNNJSA-N 0.000 description 1
- JWZDBSDWWKOHJH-HRQSHJORSA-N NC=1C2=C(N=CN=1)N(C=C2)[C@H]1[C@@H]([C@@]([C@H](O1)COC1=CC=C2C=CC=NC2=C1)(O)C)O Chemical compound NC=1C2=C(N=CN=1)N(C=C2)[C@H]1[C@@H]([C@@]([C@H](O1)COC1=CC=C2C=CC=NC2=C1)(O)C)O JWZDBSDWWKOHJH-HRQSHJORSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 101100109397 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-8 gene Proteins 0.000 description 1
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- BDUHCSBCVGXTJM-IZLXSDGUSA-N Nutlin-3 Chemical compound CC(C)OC1=CC(OC)=CC=C1C1=N[C@H](C=2C=CC(Cl)=CC=2)[C@H](C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)NCC1 BDUHCSBCVGXTJM-IZLXSDGUSA-N 0.000 description 1
- 229920000305 Nylon 6,10 Polymers 0.000 description 1
- JOLPMNSROALHES-UHFFFAOYSA-L O.O.O.[Ru](Cl)Cl Chemical compound O.O.O.[Ru](Cl)Cl JOLPMNSROALHES-UHFFFAOYSA-L 0.000 description 1
- HQMOUBOMFSGBNR-YNXVLUOKSA-N O1C(C)(C)OC[C@@H]1[C@@H]1[C@@](C=C)(O)[C@H]2OC(C)(C)O[C@H]2O1 Chemical compound O1C(C)(C)OC[C@@H]1[C@@H]1[C@@](C=C)(O)[C@H]2OC(C)(C)O[C@H]2O1 HQMOUBOMFSGBNR-YNXVLUOKSA-N 0.000 description 1
- WJJHDOIEXYAJGL-UHFFFAOYSA-N OC(COC1=CC=C2)C12O Chemical compound OC(COC1=CC=C2)C12O WJJHDOIEXYAJGL-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 101150023417 PPARG gene Proteins 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 101710183160 Serine/threonine-protein kinase PLK1 Proteins 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 238000006579 Tsuji-Trost allylation reaction Methods 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229940127507 Ubiquitin Ligase Inhibitors Drugs 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(e)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- CKXIPXAIFMTQCS-LRDUUELOSA-N [2-[(2s,4s)-4-[(2r,3r,4r,5s,6s)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 3-aminopropanoate Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)COC(=O)CCN)[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@H]1F CKXIPXAIFMTQCS-LRDUUELOSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 1
- 229960004103 abiraterone acetate Drugs 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 150000007960 acetonitrile Chemical class 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- DUYNJNWVGIWJRI-LJAQVGFWSA-N acolbifene Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(O)C=C3O2)C)C=2C=CC(O)=CC=2)=CC=C1OCCN1CCCCC1 DUYNJNWVGIWJRI-LJAQVGFWSA-N 0.000 description 1
- 229950002421 acolbifene Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940037127 actonel Drugs 0.000 description 1
- 229940060205 adagen Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229940064305 adrucil Drugs 0.000 description 1
- 229950005033 alanosine Drugs 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940110282 alimta Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical group 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-M alpha-D-galacturonate Chemical compound O[C@H]1O[C@H](C([O-])=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-M 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229950001104 anhydrovinblastine Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000454 anti-cipatory effect Effects 0.000 description 1
- 230000002973 anti-dopamine Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 229940014583 arranon Drugs 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- TWHSQQYCDVSBRK-UHFFFAOYSA-N asulacrine Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
- 229950011088 asulacrine Drugs 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- SHZPNDRIDUBNMH-NIJVSVLQSA-L atorvastatin calcium trihydrate Chemical compound O.O.O.[Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 SHZPNDRIDUBNMH-NIJVSVLQSA-L 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- PNPBGYBHLCEVMK-UHFFFAOYSA-L benzylidene(dichloro)ruthenium;tricyclohexylphosphane Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-L 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229940110331 bextra Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229940108502 bicnu Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- UBJAHGAUPNGZFF-XOVTVWCYSA-N bms-184476 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OCSC)C(=O)C1=CC=CC=C1 UBJAHGAUPNGZFF-XOVTVWCYSA-N 0.000 description 1
- GMJWGJSDPOAZTP-MIDYMNAOSA-N bms-188797 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)OC)C(=O)C1=CC=CC=C1 GMJWGJSDPOAZTP-MIDYMNAOSA-N 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 229940028101 boniva Drugs 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229940112133 busulfex Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 108010031379 centromere protein E Proteins 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- IQCIQDNWBGEGRL-UHFFFAOYSA-N chembl1614651 Chemical compound O=C1C2=C(O)C=CC(O)=C2N2N=C(CNCCO)C3=CC=C(NCCCN)C1=C32 IQCIQDNWBGEGRL-UHFFFAOYSA-N 0.000 description 1
- ROWSTIYZUWEOMM-UHFFFAOYSA-N chembl488755 Chemical compound C12=CC=CC=C2C(=O)C2=C1C1=CC=C(O)C=C1N=C2NCCN(C)C ROWSTIYZUWEOMM-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- MNKYQPOFRKPUAE-UHFFFAOYSA-N chloro(triphenyl)silane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 MNKYQPOFRKPUAE-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 229950009003 cilengitide Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 229940103380 clolar Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- UWCHSDIUMBNDLT-UHFFFAOYSA-L copper;methylsulfanylmethane;dibromide Chemical compound CSC.Br[Cu]Br UWCHSDIUMBNDLT-UHFFFAOYSA-L 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- POADTFBBIXOWFJ-VWLOTQADSA-N cositecan Chemical compound C1=CC=C2C(CC[Si](C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 POADTFBBIXOWFJ-VWLOTQADSA-N 0.000 description 1
- 229940088547 cosmegen Drugs 0.000 description 1
- 229940066901 crestor Drugs 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940094488 cytarabine liposome Drugs 0.000 description 1
- 230000010250 cytokine signaling pathway Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 229940070968 depocyt Drugs 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229950007457 dibrospidium chloride Drugs 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical compound CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- LFQCJSBXBZRMTN-OAQYLSRUSA-N diflomotecan Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC(F)=C(F)C=C3N=C21 LFQCJSBXBZRMTN-OAQYLSRUSA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000005906 dihydroxylation reaction Methods 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229950009278 dimesna Drugs 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- AXAZMDOAUQTMOW-UHFFFAOYSA-N dimethylzinc Chemical compound C[Zn]C AXAZMDOAUQTMOW-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- GDLPAGOVHZLZEK-JBUFHSOLSA-L disodium;(4s)-4-amino-5-[[(1s)-1-carboxylato-2-(1h-indol-3-yl)ethyl]amino]-5-oxopentanoate Chemical compound [Na+].[Na+].C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC([O-])=O)N)C([O-])=O)=CNC2=C1 GDLPAGOVHZLZEK-JBUFHSOLSA-L 0.000 description 1
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- OAIHMBRTKDWZQG-WFVUJJAZSA-L disodium;[(8r,9s,13s,14s,17s)-3-[bis(2-chloroethyl)carbamoyloxy]-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] phosphate;hydrate Chemical compound O.[Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 OAIHMBRTKDWZQG-WFVUJJAZSA-L 0.000 description 1
- IWLDTXOHXPDPQG-UHFFFAOYSA-L disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-3-pyrrolidin-1-ylpropyl]phosphinate Chemical compound [Na+].[Na+].OP(=O)(O)C(P([O-])([O-])=O)(O)CCN1CCCC1 IWLDTXOHXPDPQG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 229940042317 doxorubicin liposome Drugs 0.000 description 1
- 229940017825 dromostanolone Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229950004438 elinafide Drugs 0.000 description 1
- 229940053603 elitek Drugs 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- 229940073038 elspar Drugs 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 229940000733 emcyt Drugs 0.000 description 1
- 229950005450 emitefur Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229940089118 epogen Drugs 0.000 description 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229940098617 ethyol Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940085363 evista Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 229940049370 fibrinolysis inhibitor Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- CEVCTNCUIVEQOY-STXHBLNNSA-N fumagillol Chemical compound C([C@@H](O)[C@H](C1[C@]2(C)[C@H](O2)CC=C(C)C)OC)C[C@@]21CO2 CEVCTNCUIVEQOY-STXHBLNNSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- XOVCEWUXUQBVHB-UHFFFAOYSA-N furan-2,3-diol Chemical compound OC=1C=COC=1O XOVCEWUXUQBVHB-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229950011325 galarubicin Drugs 0.000 description 1
- 229950004410 galocitabine Drugs 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229950011595 glufosfamide Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229940003183 hexalen Drugs 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- 229960003911 histrelin acetate Drugs 0.000 description 1
- 238000011905 homologation Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000046485 human PRMT2 Human genes 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- 229940090411 ifex Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 229940063199 kenalog Drugs 0.000 description 1
- 229940065223 kepivance Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229940095570 lescol Drugs 0.000 description 1
- 229940063725 leukeran Drugs 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229950000909 lometrexol Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 lurtotecan Drugs 0.000 description 1
- 229940100029 lysodren Drugs 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940090004 megace Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229940101533 mesnex Drugs 0.000 description 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- RBMIFLUDJHVUDS-UHFFFAOYSA-N methyl 2-amino-4-bromo-6-fluorobenzoate Chemical compound COC(=O)c1c(N)cc(Br)cc1F RBMIFLUDJHVUDS-UHFFFAOYSA-N 0.000 description 1
- OVLUFZHAPSKJJO-UHFFFAOYSA-N methyl 7h-pyrrolo[2,3-d]pyrimidine-4-carboxylate Chemical compound COC(=O)C1=NC=NC2=C1C=CN2 OVLUFZHAPSKJJO-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- FJLBFSROUSIWMA-UHFFFAOYSA-N metyrapone Chemical compound C=1C=CN=CC=1C(C)(C)C(=O)C1=CC=CN=C1 FJLBFSROUSIWMA-UHFFFAOYSA-N 0.000 description 1
- 229960004465 metyrapone Drugs 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 229960004438 mibefradil Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000008600 mitotic progression Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 229940090009 myleran Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- XXHOHJTVFUJJMT-UHFFFAOYSA-N n-(3-bromophenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(Br)=C1 XXHOHJTVFUJJMT-UHFFFAOYSA-N 0.000 description 1
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- ZDUZYDDAHVZGCI-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethylpyrido[4,3-b]carbazole-1-carboxamide Chemical compound CN1C2=CC=C(O)C=C2C2=C1C(C)=C1C=CN=C(C(=O)NCCN(C)C)C1=C2 ZDUZYDDAHVZGCI-UHFFFAOYSA-N 0.000 description 1
- XBGNERSKEKDZDS-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]acridine-4-carboxamide Chemical compound C1=CC=C2N=C3C(C(=O)NCCN(C)C)=CC=CC3=CC2=C1 XBGNERSKEKDZDS-UHFFFAOYSA-N 0.000 description 1
- OSFCMRGOZNQUSW-UHFFFAOYSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10h-acridine-4-carboxamide Chemical compound N1C2=C(OC)C=CC=C2C(=O)C2=C1C(C(=O)NC1=CC=C(C=C1)CCN1CCC=3C=C(C(=CC=3C1)OC)OC)=CC=C2 OSFCMRGOZNQUSW-UHFFFAOYSA-N 0.000 description 1
- GWLFIMOOGVXSMZ-UHFFFAOYSA-N n-[[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxothioxanthen-4-yl]methyl]formamide Chemical compound S1C2=CC=C(OC)C=C2C(=O)C2=C1C(CNC=O)=CC=C2NCCN(CC)CC GWLFIMOOGVXSMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UBWXUGDQUBIEIZ-QNTYDACNSA-N nandrolone phenpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-QNTYDACNSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229940109551 nipent Drugs 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229950000891 nolatrexed Drugs 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-M novobiocin(1-) Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C([O-])=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-M 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229940099216 oncaspar Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 229940100027 ontak Drugs 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229910000487 osmium oxide Inorganic materials 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- 229960002502 paclitaxel protein-bound Drugs 0.000 description 1
- 229960002404 palifermin Drugs 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 229940096763 panretin Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001218 pegademase Drugs 0.000 description 1
- 229940048111 pegademase bovine Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- CRWVOXFUXPYTRK-UHFFFAOYSA-N pent-4-yn-1-ol Chemical compound OCCCC#C CRWVOXFUXPYTRK-UHFFFAOYSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- LCEFEIBEOBPPSJ-UHFFFAOYSA-N phenyl selenohypobromite Chemical compound Br[Se]C1=CC=CC=C1 LCEFEIBEOBPPSJ-UHFFFAOYSA-N 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- WLJVNTCWHIRURA-UHFFFAOYSA-M pimelate(1-) Chemical compound OC(=O)CCCCCC([O-])=O WLJVNTCWHIRURA-UHFFFAOYSA-M 0.000 description 1
- 229950004317 pinafide Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 229950008499 plitidepsin Drugs 0.000 description 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- 229940098901 polifeprosan 20 Drugs 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940089484 pravachol Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 101150097768 prmt5 gene Proteins 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 229950007401 pumitepa Drugs 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- UCFSULAKAYDAAE-UHFFFAOYSA-N quinolin-1-ium;iodide Chemical compound I.N1=CC=CC2=CC=CC=C21 UCFSULAKAYDAAE-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940100552 retinamide Drugs 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229940120975 revlimid Drugs 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 229960001302 ridaforolimus Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 229960003271 rosiglitazone maleate Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 229940053186 sclerosol Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- NSFFYSQTVOCNLX-JKIHJDPOSA-M sodium;[(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadecyl phosphate;hydrate Chemical compound O.[Na+].O[C@H]1[C@H](O)[C@@H](COP([O-])(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 NSFFYSQTVOCNLX-JKIHJDPOSA-M 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 229960005566 swainsonine Drugs 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
- MXFWWQICDIZSOA-UHFFFAOYSA-N talinolol Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1NC(=O)NC1CCCCC1 MXFWWQICDIZSOA-UHFFFAOYSA-N 0.000 description 1
- 229960003658 talinolol Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003102 tasonermin Drugs 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- PGRYKXHGSUUZSH-KFRQHLNQSA-N tert-butyl (1S,2R,6S,7R)-2,4,4-trimethyl-9-oxo-3,5-dioxa-8-azatricyclo[5.2.1.02,6]decane-8-carboxylate Chemical compound C[C@@]12[C@@H]3C[C@H]([C@@H]1OC(O2)(C)C)N(C3=O)C(=O)OC(C)(C)C PGRYKXHGSUUZSH-KFRQHLNQSA-N 0.000 description 1
- VOHGDRVRTPLFPS-UHFFFAOYSA-N tert-butyl N-[(2-methylpropan-2-yl)oxycarbonyl]-N-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)carbamate Chemical compound CC=1C2=C(N=C(N=1)N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)NC=C2 VOHGDRVRTPLFPS-UHFFFAOYSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229950000185 tozasertib Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- LGSAOJLQTXCYHF-UHFFFAOYSA-N tri(propan-2-yl)-tri(propan-2-yl)silyloxysilane Chemical compound CC(C)[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)C(C)C LGSAOJLQTXCYHF-UHFFFAOYSA-N 0.000 description 1
- LHJCZOXMCGQVDQ-UHFFFAOYSA-N tri(propan-2-yl)silyl trifluoromethanesulfonate Chemical compound CC(C)[Si](C(C)C)(C(C)C)OS(=O)(=O)C(F)(F)F LHJCZOXMCGQVDQ-UHFFFAOYSA-N 0.000 description 1
- 229960005526 triapine Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940062627 tribasic potassium phosphate Drugs 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229940086984 trisenox Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 229950010147 troxacitabine Drugs 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940001814 uvadex Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229940054937 valstar Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 229940053890 zanosar Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229940061261 zolinza Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- 229940088909 zyloprim Drugs 0.000 description 1
- VLCYCQAOQCDTCN-ZCFIWIBFSA-N α-difluoromethylornithine Chemical compound NCCC[C@@](N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-ZCFIWIBFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Description
Xは、CH2又はOであり;
Yは、CH2、NH、又はOであり;
Z1は、CR4又はNであり;
Z2、Z3、Z4及びZ5は、独立に、N又はCR9から選択され;
A1は、CH又はNであり;
A2は、CR10又はNであり;
A3は、CH又はNであり;
A4は、CR8又はNであり;
R1、R2及びR7は次の通りであり:
i)R1は、H、CCH、又は1~2個のハロゲンで置換されていても良いC1-3アルキルであり;R2は、H、ハロゲン、OH、CH3、NH2、NHCH3、CH2OH、CH2F又はCHF2であり、そして、R7はHであり、但しR1及びR2が同時にHであることはできず;又は
ii)R1及びR7が一緒になって、1~3個のハロゲンで置換されていても良い5員炭素環又は1個のO原子を含む5員複素環アルキル環を形成し、そして、R2は、H、OH、CH3、CHF2又はFであり;
R3は、H、ハロゲン、NH2、NHCH3、CN、OH、OCH3、1~3個のハロゲン若しくはOHで置換されていても良いC1-4アルキル、又は1~3個のハロゲン若しくはOHで置換されていても良いC3-5シクロアルキルであり;
R5は、H、NH2又はNHR6であり;
R4は、存在する場合、H、ハロゲン、CH3、CHF2又はCF3であり;又は
R4及びR5が、それらが結合している炭素原子と一緒になって、1個のN原子を含む5員複素環アルキルを形成し、ここで、複素環アルキルは、ハロゲン、CH3、CF3又はCF2Hから独立に選択される1~4個の置換基で置換されていても良く;
R6は、存在する場合、CH3、C2H5、CH2CH2CH3、CH(CH3)2、CH2CHF2、CH2CF3又はCH2-シクロプロピルであり;
R8は、存在する場合、H、ハロゲン、1~3個のハロゲンで置換されていても良いC1-4アルキル、1~3個のハロゲンで置換されていても良いC3-5シクロアルキル、又は1~3個のハロゲンで置換されていても良いアリールであり;
各R9は、存在する場合、H又はハロゲンから独立に選択され;そして
R10は、存在する場合、H、C1-6アルキル、NH2又はハロゲンである。
Xは、CH2又はOであり;
Yは、CH2、NH又はOであり;
Z1は、CR4又はNであり;
Z2は、CH又はNであり;
Z3は、CH又はNであり;
Z4は、CH又はNであり;
A1は、CH又はNであり;
A2は、CH、N、CNH2又はCCH3であり;
A3は、CH又はNであり;
A4は、CR8又はNであり;
R1、R2及びR7は次の通りであり;
i)R1は、H、CCH、又は、1~2個のハロゲンで置換されていても良いC1-3アルキルであり;R2は、H、ハロゲン、OH、CH3、NH2、NHCH3、CH2OH、CH2F、又はCHF2であり、そして、R7はHであり、但しR1及びR2が同時にHであることはできず;又は
ii)R1及びR7が一緒になって5員環を形成し、そして、R2は、H、OH、CH3、CHF2又はFであり;
R3は、H、ハロゲン、CH3、C2H5、シクロプロピル、NH2、NHCH3、CN、CF3、OH、OCH3、又はCHF2であり;
R4は、存在する場合、H、ハロゲン、CH3、CHF2、又はCF3であり;そして、R5は、H、NH2又はNHR6であり;又は
R4及びR5が、それらが結合している炭素原子と一緒になって、1個のN原子を含む5員複素環アルキルを形成し、ここで、複素環アルキルは、ハロゲン、CH3、CF3又はCF2Hから独立に選択される1~4個の置換基で置換されていても良く;
R6は、存在する場合、CH3、C2H5、CH2CH2CH3、CH(CH3)2、CH2CHF2、CH2CF3、又はCH2-シクロプロピルであり;そして
R8は、存在する場合、H、C1-4アルキル、又はハロゲンである。
(1R,2S,3R,5R)-5-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-3-(4-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1-メチルシクロペンタン-1,2-ジオール、
(1R,2S,3R,5R)-5-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1-メチルシクロペンタン-1,2-ジオール、
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-エチニルテトラヒドロフラン-3,4-ジオール、
(2R,3S,4R,5R)-2-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2,3-ジメチルテトラヒドロフラン-3,4-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルテトラヒドロフラン-3,4-ジオール、
(2R,3S,4R,5R)-2-{[(2-アミノ-3-ブロモキノリン-7-イル)オキシ]メチル}-5-(4-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルテトラヒドロフラン-3,4-ジオール、
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-メトキシ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2-メチルテトラヒドロフラン-3,4-ジオール、
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2-メチルテトラヒドロフラン-3,4-ジオール、
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルテトラヒドロフラン-3,4-ジオール、
(1S,2R,3S,5R)-3-[2-(2-アミノ-3-ブロモ-7-キノリニル)エチル]-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチル-1,2-シクロペンタンジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4R,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3,8-ジフルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-クロロ-5-フルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-クロロ-8-フルオロキノリン-7-イル)メチル]-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(ジフルオロメチル)キノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3,5-ジフルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((6-アミノ-7-フルオロ-1,5-ナフチリジン-3-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロ-8-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3,6-ジフルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((7-アミノ-6-クロロ-1,8-ナフチリジン-2-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3,5-ジフルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-2-(4-アミノ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-4-((2-アミノ-3-クロロキノリン-7-イル)メチル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-2-(4-アミノ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-[(2-アミノ-3,5-ジフルオロキノリン-7-イル)メチル]-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-[(2-アミノ-3-クロロ-5-フルオロキノリン-7-イル)メチル]-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-2-(4-アミノ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-ブロモキノリン-7-イル)メチル]-2-[4-アミノ-5-(ジフルオロメチル)-7H-ピロロ[2,3-d]ピリミジン-7-イル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-2-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(2-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール二塩酸塩、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-2-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-[(2-アミノ-3-クロロキノリン-7-イル)メチル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-2-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-ブロモキノリン-7-イル)オキシ]-2-(4-アミノ-5-フェニル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-5-シクロプロピル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-[4-アミノ-5-(ジフルオロメチル)-7H-ピロロ[2,3-d]ピリミジン-7-イル]-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-ブロモキノリン-7-イル)オキシ]-2-(4-アミノ-5-シクロプロピル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-5,5-ジフルオロヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,5S,6S,6aR)-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-5-フルオロヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,5S,6S,6aR)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]-5-フルオロヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-((2,2,2-トリフルオロエチル)アミノ)キノリン-7-イル)オキシ)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-((シクロプロピルメチル)アミノ)キノリン-7-イル)オキシ)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)オキシ)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)オキシ)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-5-エチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)オキシ)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)オキシ)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2,3-ジヒドロ-1H-ピロロ[2,3-b]キノリン-7-イル)オキシ)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(トリフルオロメチル)キノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-ブロモキノリン-7-イル)オキシ]-2-[4-(ヒドロキシメチル)-7H-ピロロ[2,3-d]ピリミジン-7-イル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-ブロモキノリン-7-イル)オキシ]-2-[4-(2-ヒドロキシプロパン-2-イル)-7H-ピロロ[2,3-d]ピリミジン-7-イル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-(ジフルオロメチル)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(2,4-ジメチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(2,4-ジメチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-5-エチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-イソプロピル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(5-フルオロ-4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-シクロプロピル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(トリフルオロメチル)キノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2,3-ジヒドロ-1H-ピロロ[2,3-b]キノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(2,4-ジメチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(2,4-ジメチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(1R,2S,3R,5R)-5-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-1-メチル-3-(4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(5-フルオロ-4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(2R,3S,4R,5R)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2-メチル-2-((キノリン-7-イルオキシ)メチル)テトラヒドロフラン-3,4-ジオール、
(2R,3S,4R,5R)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチル-2-((キノリン-7-イルオキシ)メチル)テトラヒドロフラン-3,4-ジオール、
(1S,2R,3R,5R)-3-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルシクロペンタン-1,2-ジオール、
(1S,2R,3R,5R)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-(((2-アミノキノリン-7-イル)オキシ)メチル)-3-メチルシクロペンタン-1,2-ジオール、
(1S,2R,5R)-3-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-(フルオロメチル)シクロペンタン-1,2-ジオール、
(1R,2S,3R,5S)-5-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1-メチルシクロペンタン-1,2-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-アミノキノリン-7-イル)オキシ)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(1R,2S,3R,5R)-5-(((2-アミノキノリン-7-イル)オキシ)メチル)-1-メチル-3-(7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール、
(1R,2S,3R,5R)-5-(((2-アミノ-3-メチルキノリン-7-イル)オキシ)メチル)-1-メチル-3-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(1S,2R,3S,5R)-3-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-3-メチル-5-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール、
(1S,2R,3S,5R)-3-(2-(2,3-ジヒドロ-1H-ピロロ[2,3-b]キノリン-7-イル)エチル)-3-メチル-5-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール、
(1R,2S,3R,5R)-5-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1,5-ジメチルシクロペンタン-1,2-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(2-アミノ-4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(ジフルオロメチル)キノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(1S,2R,3R,5R)-3-(2-(2-アミノ-3-フルオロキノリン-7-イル)エチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルシクロペンタン-1,2-ジオール、
(1R,2S,3R,5S)-5-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1,5-ジメチルシクロペンタン-1,2-ジオール、
(1R,2S,3S,4R)-1-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-4-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2-メチルシクロペンタン-1,2,3-トリオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)アミノ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6a-メチルヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-メチルキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(1S,2R,3S,5R)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-(2-(2,3-ジヒドロ-1H-ピロロ[2,3-b]キノリン-7-イル)エチル)-3-メチルシクロペンタン-1,2-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(2-アミノ-4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(ジフルオロメチル)キノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6R,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(2-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6R,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(3aS,4S,5R)-1-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロ-1H-シクロペンタ[c]フラン-3a,4(3H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロフロ[3,4-b]フラン-3,3a(4H)-ジオール、
(2R,3R,3aS,6R,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロフロ[3,4-b]フラン-3,3a(4H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロフロ[3,4-b]フラン-3,3a(4H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロフロ[3,4-b]フラン-3,3a(4H)-ジオール、又は
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(ジフルオロメチル)キノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
又は薬学的に許容されるその塩である。
一般的方法
本発明の化合物は、例えば刊行文書に記載の公知の方法によって公知の化合物又は市販の化合物から容易に製造することができ、下記で記載の製造方法によって製造することができる。本発明は、下記で記載の製造方法に限定されるものではない。本発明はまた、本発明の化合物の製造方法を含むものである。
AcOH:酢酸
ADDP:1,1′-(アゾジカルボニル)ジピペリジン
AIBN:α,α′-アゾイソブチロニトリル
Ar:アリール
Atm:気圧
Aq.:水系
9-BBN:9-ボラビシクロ(3.3.1)ノナン
BBN:ボラビシクロ(3.3.1)ノナン
BnBr:臭化ベンジル
BOC:ブチルオキシカルボニル
BSA:ウシ血清アルブミン
Bz:ベンゾイル
℃:摂氏
conc.:濃度
CDCl3:重クロロホルム
CD3OD:重メタノール
CO:一酸化炭素
Cs2CO3:炭酸セシウム
CuBrMe2S:臭化銅ジメチルスルフィド
DAST:ジエチルアミノ硫黄三フッ化物
DBU:1,8-ジアザビシクロ[5.4.0]ウンデカ-7-エン
DCA:ジクロロ酢酸
DCE:1,2-ジクロロエタン
DCM:ジクロロメタン
DDQ:2,3-ジクロロ-5,6-ジシアノ-p-ベンゾキノン
DIAD:ジイソプロピルアゾジカルボキシレート
DIEA:N,N-ジイソプロピルエチルアミン
DEAD:ジ-tert-ブチルアゾジカルボキシレート
DMAP:4-(ジメチルアミノ)ピリジン
DMF:N,N-ジメチルホルムアミド
DMSO:ジメチルスルホキシド
DMP:デス-マーチンペルヨージナン
DMTr:4,4′-ジメトキシトリチル
dppf:1,1′-ビス(ジフェニルホスフィノ)フェロセン
DTT:ジチオトレイトール
eq:当量(モル)
EDC:N-(3-ジメチルアミノプロピル)-N′-エチルカルボジイミド
EtOAc:酢酸エチル
EtOH:エタノール
g:グラム
h:時間
HATU:N-[(ジメチルアミノ)-1H-1,2,3-トリアゾロ-[4,5-b]ピリジン-1-イルメチレン]-N-メチルメタンアミニウムヘキサフルオロホスフェートN-オキサイド
HCl:塩酸
HMPA:ヘキサメチルホスホラミド
HPLC:高速液体クロマトグラフィー
IBX:2-ヨードオキシ安息香酸
Im:イミダゾール
LCMS:液体クロマトグラフィー及び質量分析
LiHMDS:リチウムビス(トリメチルシリル)アミド
M:モル
m-CPBA:メタ-クロロ過安息香酸
MeCN:アセトニトリル
MeOH:メタノール
MePPh3Br:メチルトリフェニルホスホニウムブロミド
MS:質量分析
MTBE:メチルtert-ブチルエーテル
mmol:ミリモル
mg:ミリグラム
min:分
mL:ミリリットル
N:規定
NaBH4:水素化ホウ素ナトリウム
NaH:水素化ナトリウム
NaHCO3:重炭酸ナトリウム
NaOH:水酸化ナトリウム
Na2SO4:硫酸ナトリウム
NH4HCO3:重炭酸アンモニウム
NH4Cl:塩化アンモニウム
nM:ナノモル
NMO:N-メチルモルホリン-N-オキサイド
NMP:N-メチル-2-ピロリドン
NMR:核磁気共鳴
OTIPS:トリイソプロピルシリルエーテル
P(n-Bu)3:トリフェニルホスフィン
PDC:二クロム酸ピリジニウム
PdCl2(dppf):[1,1-ビス(ジフェニルホスフィン)フェロセン]ジクロロパラジウム(II)
Pd(PPh3)4:テトラキス(トリフェニルホスフィン)パラジウム(0)
Ph:フェニル
Ph3P/PPh3:トリフェニルホスフィン
PMP:P-メトキシベンジル
POCl3:オキシ塩化リン(V)
Pol:ポリマー結合
psi:ポンド/平方インチ
pTsOH:p-トルエンスルホン酸
py:ピリジン
rt:室温
Rh(nbd)2BF4:ビス(ノルボルナジエン)ロジウム(I)テトラフルオロボレート
RuPhos Pd G3:(2-ジシクロヘキシルホスフィノ-2′,6′-ジイソプロポキシ-1,1′-ビフェニル)[2-(2′-アミノ-1,1′-ビフェニル)]パラジウム(II)メタンスルホネート
sat.:飽和
SFC:超臨界流体クロマトグラフィー
SM:原料
SOCl2:塩化チオニル
t-BuOK:カリウムt-ブトキシド
TBAF:フッ化テトラブチルアンモニウム
TBAI:ヨウ化テトラブチルアンモニウム
TBDPS:tert-ブチルジフェニルシリル
TBDPSO:tert-ブチルジフェニルシリルエーテル
TBDPSCl:tert-ブチル(クロロ)ジフェニルシラン
TBHP:tert-ブチルヒドロペルオキシド
TEA:トリエチルアミン
Tf:トリフリル
TFA:トリフルオロ酢酸
THF:テトラヒドロフラン
TIPS:トリイソプロピルシリル
TIPSOTf:トリイソプロピルシリルトリフルオロメタンスルホネート
TLC:薄層クロマトグラフィー
TMS:トリメチルシリル
TMSOTf:トリメチルシリルトリフルオロメタンスルホネート
TsCl:トルエンスルホニルクロライド
TsOH:p-トルエンスルホン酸
Prep-TLC:分取TLC
μL:ミクロリットル
Xantphos Pd G3:メタンスルホナト[4,5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン](2′-アミノ-1,1′-ビフェニル-2-イル)パラジウム(II)
vol:体積。
以上、上記の具体例とともに本発明について説明したが、本発明の多くの変更、修正及び変形形態が当業者には明らかであろう。場合により、反応図式の段階を行う順序を変えて、反応を促進したり又は望ましくない反応を回避することができる。そのような変更、修正及び変形形態は、いずれも本発明の精神及び範囲に包含されるものである。原料及び中間体は、商業的入手先から購入されるか、公知の手順から製造されるか、他の形で例示される。
段階1:ベンゾ[d]チアゾール-2-チオール(50g、300mmol)の1,4-ジオキサン(125mL)及び水(125mL)中の溶液に、0℃で水酸化カリウム(30g、540mmol)を加えた。過剰のクロロジフルオロメタンを、得られた混合物に5時間かけて吹き込んだ。リアクターを密閉し、混合物を室温で8時間攪拌してから、減圧下に濃縮した。残留物をシリカでのカラムクロマトグラフィー(トリエチルアミンで中和)(0%から30%酢酸エチル/ヘキサン)によって精製して、2-((ジフルオロメチル)チオ)ベンゾ[d]チアゾールを得た。MS: 218 (M+1). 1H-NMR (300 MHz, クロロホルム-d) δ 8.05 - 8.02 (m, 1H), 7.89 - 7.86 (m, 1H), 7.67 - 7.41 (m, 3H). 19F-NMR (282 MHz, クロロホルム-d) δ -93.20 (s, CF2H).
テトラヒドロフラン(12mL)に溶かしたメチル7H-ピロロ[2,3-d]ピリミジン-4-カルボキシレート(0.52g、2.9mmol)を窒素でパージし、冷却して-78℃とした。その溶液に、メチルマグネシウムブロミド(1.4M、4.6mL、6.5mmol)を加え、反応液を昇温させて室温とし、1時間攪拌した。2時間後、追加のメチルマグネシウムブロミド(1.4M、4.6mL、6.5mmol)を-78℃で加え、反応液を18時間攪拌し、昇温させて室温とした。飽和塩化アンモニウム水溶液で反応停止し、室温で1時間攪拌した。有機層を分離し、ブラインで洗浄し、硫酸ナトリウムで脱水し、溶媒を減圧下に除去して、2-(7H-ピロロ[2,3-d]ピリミジン-4-イル)プロパン-2-オールを得て、それをそれ以上精製せずに用いた。MS:178(M+1)。
段階1:4-クロロ-5-ヨード-1H-ピロロ[2,3-d]ピリミジン(10.0g、35.8mmol)のTHF(119mL)中の攪拌混合物に、0℃でトリエチルアミン(12.5mL、89.0mmol)及び(2-(クロロメトキシ)エチル)トリメチルシラン(7.60mL、42.9mmol)を加えた。混合物を昇温させて室温とし、終夜攪拌した。混合物を水で処理し、EtOAcで抽出した。合わせた有機層をブラインで洗浄し、硫酸ナトリウムで脱水し、減圧下に濃縮し、シリカでのカラムクロマトグラフィー(0%から10%EtOAc/DCM)によって精製して、4-クロロ-5-ヨード-7-{[2-(トリメチルシリル)エトキシ]メチル}-7H-ピロロ[2,3-d]ピリミジンを得た。MS: 410 (M+1). 1H NMR (500 MHz, DMSO-d6) δ 8.69 (s, 1H), 8.13 (s, 1H), 5.60 (s, 2H), 3.57‐3.45 (m, 2H), 0.87‐0.75 (m, 2H), -0.10 (s, 9H).
段階1:メチル2-アミノ-4-ブロモ-6-フルオロベンゾエート(5.0g、20mmol)を窒素雰囲気下にTHF(40mL)に溶かし、冷却して0℃とした。水素化リチウムアルミニウム(1M THF中溶液、40.3mL、40.3mmol)を、攪拌溶液に滴下した。反応液を3時間攪拌し、冷却して0℃とした。水(2mL)、水酸化ナトリウム(1N水溶液、3mL)及び水(6mL)をその順で滴下することで反応停止した。硫酸マグネシウムを加え、30分間攪拌した。溶液をセライト(登録商標)層によって濾過し、減圧下に溶媒を除去した。残留物をシリカでのカラムクロマトグラフィー(0%から30%DCM/3:1EtOAc/EtOH)によって精製して、(2-アミノ-4-ブロモ-6-フルオロフェニル)メタノールを得た。MS:202/204(M-18/M-16)。
2-アミノ-4-ブロモ-3-フルオロベンズアルデヒド(1.8g、8.3mmol)及び鉄粉(4.6g、80mmol)を含むフラスコを窒素でパージし、THF(16.5mL)、トリクロロアセトニトリル(1.2mL、12mmol)を入れ、65℃まで終夜加熱させた。反応液を冷却して室温とし、濾過し、EtOAcで洗浄した。有機層を減圧下に濃縮し、残留物をシリカでのカラムクロマトグラフィー(0%から100%EtOAc/DCM)によって精製した。生成物含有分画を減圧下に濃縮した。残留物をTHF(50mL)に溶かし、N-プロピルジエタノールアミン-官能化シリカゲル(0.84mmol/g)を入れ、終夜攪拌した。シリカをセライト(登録商標)層によって濾去し、THF(50mL)で洗浄した。有機層を減圧下に濃縮して、7-ブロモ-3-クロロ-8-フルオロキノリン-2-アミンを得た。MS: 275/277 (M+1/M+3). 1H NMR (500 MHz, DMSO-d6) δ 8.32 (s, 1H), 7.48‐7.45 (m, 1H), 7.41 (m, 1H), 7.26 (br s, 2H).
段階1:(3R,3aS,6aR)-3a-(ベンジルオキシ)-6-メチレンヘキサヒドロ-2H-シクロペンタ[b]フラン-2,3-ジオール(1.0g、3.8mmol)の脱水アセトニトリル(60mL)中の攪拌溶液に、0℃でアルゴン雰囲気下に(E)-ジアゼン-1,2-ジイルビス(ピペリジン-1-イルメタノン)(1.54g、6.1mmol)を滴下し、続いて、トリブチルホスフィン(1.4mL、5.7mmol)を滴下した。得られた混合物を35℃で1時間攪拌した。別の容器中、4-クロロ-5-(ジフルオロメチル)-7H-ピロロ[2,3-d]ピリミジン(1.1g、5.3mmol)の脱水アセトニトリル(25mL)中の攪拌溶液に、アルゴン雰囲気下に室温でDBU(0.86mL、5.7mmol)を加えた。得られた混合物を室温で30分間攪拌した。DBU溶液を注射器によって上記のエポキシド含有溶液に移した。最終混合物を35℃で16時間攪拌した。反応混合物を、飽和塩化アンモニウム水溶液(150mL)を加えることによって反応停止し、酢酸エチルで抽出した(100mLで3回)。合わせた有機層をブライン(100mL)で洗浄し、無水硫酸ナトリウムで脱水し、濾過した。濾液を減圧下に濃縮した。生成物をシリカでのカラムクロマトグラフィー(0%から30%酢酸エチル/石油エーテル)によって精製して、(2R,3R,3aS,6aR)-3a-(ベンジルオキシ)-2-(4-クロロ-5-(ジフルオロメチル)-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-メチレンヘキサヒドロ-2H-シクロペンタ[b]フラン-3-オールを得た。MS: 448(M+1). 1H NMR (300 MHz, DMSO-d6) δ 8.84 (s, 1H), 7.61 - 7.21 (m, 7H), 6.16 (d, J = 8.1 Hz, 1H), 5.77 (d, J = 6.3 Hz, 1H), 5.21 - 5.14 (m, 3H), 4.94 (d, J = 12.0 Hz, 1H), 4.72 - 4.66 (m, 2H), 2.85 - 2.75 (m, 1H), 2.59 - 2.54 (m, 1H), 2.28 - 2.25 (m, 1H), 2.07 - 2.00 (m, 1H). 19F NMR (282 MHz, DMS
O-d6) δ -109.36 (d, 1F), -114.08 (d, 1F).
段階1:(3R,3aS,6R,6aR)-2-メトキシヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a,6-トリオール(2g、10mmol)を脱水トルエン(5mLで3回)と共留去し、アセトン(50mL)に再溶解させた。この溶液に4-メチルベンゼンスルホン酸(0.091g、0.53mmol)を加え、続いて、2,2-ジメトキシプロパン(2.74g、26.3mmol)を加えた。得られた混合物を環境温度で1時間攪拌した。得られた溶液のpHを、0℃にて飽和NaHCO3水溶液(50mL)で調節して8とした。得られた混合物をEtOAcで抽出した(150mLで3回)。合わせた有機層をブライン(100mL)で洗浄し、無水Na2SO4で脱水し、濾過し、濾液を減圧下に濃縮した。残留物をシリカでのカラムクロマトグラフィー(EtOAc/石油エーテル)によって精製して、(3aR,5aR,6R,8aR)-4-メトキシ-2,2-ジメチルヘキサヒドロシクロペンタ[2,3]フロ[3,4-d][1,3]ジオキソール-6-オールを得た。MS: 248.20 (M+NH4). 1H NMR (300 MHz, DMSO-d6) δ 4.96 (s, 1H), 4.41 (d, J = 5.1 Hz, 1H), 4.17 (s, 1H), 4.10 (d, J = 6.0 Hz, 1H), 3.88-3.79 (m, 1H), 3.33 (s, 3H), 2.04-1.92 (m, 1H), 1.76-1.62 (m, 3H), 1.39 (s, 3H), 1.31 (s, 3H).当該カラムを45%から50%EtOAc/石油エーテルでさらに溶離して、(3aR,5aR,6R,8aR)-4-メトキシ-2,2-ジメチルヘキサヒドロシクロペンタ[2,3]フロ[3,4-d][1,3]ジオキソール-6-オールを得た。MS: 248 (M+NH4). 1H NMR (300 MHz, DMSO-d6) δ 4.92 (d, J = 4.2 Hz, 1H), 4.72 (d, J = 6.0 Hz, 1H), 4.35 (d, J = 4.2 Hz, 1H), 4.00 (d, J = (5.4 Hz, 1H), 3.91-3.82 (m, 1H), 3.35 (s, 3H), 2.09-1.97 (m, 1H), 1.83-1.62 (m, 2H), 1.52-1.43 (m, 1H), 1.40 (s, 3H), 1.31 (s, 3H).
段階1:(3aR,5S,6R,6aR)-5-((R)-2,2-ジメチル-1,3-ジオキソラン-4-イル)-2,2-ジメチルテトラヒドロフロ[2,3-d][1,3]ジオキソール-6-オール(200g、768mmol)のDCM(1000mL)中の攪拌溶液に、室温で重クロム酸ピリジニウム(170g、760mmol)及び無水酢酸(220mL、2.3mol)を加えた。得られた混合物を40℃で2時間攪拌した。混合物を減圧下に濃縮し、残留物をシリカでのカラムクロマトグラフィー(10%から40%EtOAc/石油エーテルによって精製して、(3aR,5R,6aS)-5-((R)-2,2-ジメチル-1,3-ジオキソラン-4-イル)-2,2-ジメチルジヒドロフロ[2,3-d][1,3]ジオキソール-6(3aH)-オンを得た。MS: 276 (M+NH4). 1H NMR (400 MHz, クロロホルム-d) δ 6.11 (d, J = 4.5 Hz, 1H), 4.42 - 4.31 (m, 2H), 4.10 - 3.95 (m, 2H), 3.44 - 3.39 (m, 1H), 1.46 - 1.41 (m, 6H), 1.31 (s, 6H).
2.19 - 2.13 (m, 1H), 2.09‐2.04 (m, 1H).
段階1:(3aR,5aR,6R,8aR)-4-メトキシ-2,2-ジメチルヘキサヒドロシクロペンタ[2,3]フロ[3,4-d][1,3]ジオキソール-6-オール(5.0g、22mmol)のDCM(40mL)中溶液に、室温で4-ジメチルアミノピリジン(2.9g、24mmol)を加えた。その混合物に、トリエチルアミン(2.4g、24mmol)を滴下し、続いて、p-トルエンスルホニルクロライド(6.2g、33mmol)を滴下した。反応混合物を25℃で16時間攪拌した。得られた混合物を飽和NH4Cl水溶液(100mL)で反応停止し、DCMで抽出した(100mLで3回)。合わせた有機層をブライン(100mL)で洗浄し、無水硫酸ナトリウムで脱水した。濾過後、濾液を減圧下に濃縮した。残留物をシリカでのカラムクロマトグラフィー(0%から27%酢酸エチル/石油エーテル)によって精製して、(3aR,5aR,6R,8aR)-4-メトキシ-2,2-ジメチルヘキサヒドロシクロペンタ[2,3]フロ[3,4-d][1,3]ジオキソール-6-イル4-メチルベンゼンスルホネートを得た。MS: 402 (M+NH4). 1H-NMR (400 MHz, DMSO-d6) δ 7.84‐7.82 (m, 2H), 7.52‐7.49 (m, 2H), 4.87 (d, J = 4.0 Hz, 1H), 4.77‐4.72 (m, 1H), 4.40 (d, J = 4.0 Hz, 1H), 3.93 (d, J = 5.2 Hz, 1H), 3.24 (s, 3H), 2.44 (s, 3H), 2.13‐2.08 (m, 1H), 1.91 ‐1.86 (m, 1H), 1.78‐1.57 (m, 2H), 1.36 (s, 3H), 1.28 (s, 3H).
段階1:(3aR,5aR,6R,8aR)-4-メトキシ-2,2-ジメチルヘキサヒドロシクロペンタ[2,3]フロ[3,4-d][1,3]ジオキソール-6-オール(2.0g、8.7mmol)の無水DCM(43mL)中溶液に、0℃で窒素雰囲気下、DMP(4.4g、10mmol)を1回で加えた。混合物を室温で終夜攪拌した。混合物をDCM(40mL)で希釈し、飽和重炭酸ナトリウム水溶液(80mL)及びチオ硫酸ナトリウム(10g、63mmol)で処理した。得られた混合物を室温で10分間攪拌した。有機層を分離し、水層をDCMで抽出した(40mLで3回)。合わせた有機層をブライン(80mL)で洗浄し、無水硫酸ナトリウムで脱水し、濾過し、減圧下に濃縮した。残留物をシリカでのカラムクロマトグラフィー(0%から60%EtOAc/ヘキサン)によって精製して、(3aR,5aS,8aS)-4-メトキシ-2,2-ジメチルテトラヒドロシクロペンタ[2,3]フロ[3,4-d][1,3]ジオキソール-6(5aH)-オンを得た。1H NMR (600 MHz, DMSO-d6) δ 4.97 (s, 1H), 4.39 (s, 1H), 4.15 (s, 1H), 3.09 (s, 3H), 2.50‐2.46 (m, 1H), 2.46‐2.40 (m, 1H), 2.40‐2.29 (m, 2H), 1.38 (s, 3H), 1.36 (s, 3H).
段階1:ナイステッド試薬(6.37g、14.0mmol)の無水THF(40mL)中混合物に、0℃でアルゴン雰囲気下に三フッ化ホウ素・ジエチルエーテラート(1.8mL、14.0mmol)を滴下した。混合物を0℃で5分間攪拌した。(3aR,4aS,7aS,7bR)-7a-(ベンジルオキシ)-6-フルオロ-2,2-ジメチルテトラヒドロ-3aH-シクロペンタ[4,5]フロ[2,3-d][1,3]ジオキソール-5(4aH)-オン(1.5g、4.7mmol)の無水THF(35mL)中溶液を0℃で加えた。得られた混合物を環境温度で15時間攪拌した。0℃で飽和NaHCO3水溶液(40mL)を加えることで反応混合物を反応停止し、それをEtOAc/H2O(250mL/50mL)の間で分配した。有機層を分離し、水層をEtOAc(100mL)で再抽出した。合わせた有機層を水(150mL)及びブライン(100mLで2回)で洗浄した。有機層を無水Na2SO4で脱水し、濾過し、濾液を減圧下に濃縮した。残留物をシリカでのカラムクロマトグラフィー(0%から10%EtOAc/石油エーテル)によって精製して、(3aR,4aR,6R,7aR,7bR)-7a-(ベンジルオキシ)-6-フルオロ-2,2-ジメチル-5-メチレンヘキサヒドロ-3aH-シクロペンタ[4,5]フロ[2,3-d][1,3]ジオキソールを得た。1H-NMR (400 MHz, CDCl3) δ 7.38‐7.29 (m, 5H), 5.99 (d, J = 3.6 Hz, 1H), 5.68‐5.64 (m, 2H), 5.57‐5.39 (m, 1H), 4.78 (s, 1H), 4.72 (d, J = 10.8 Hz, 1H), 4.64 (d, J = 4.0 Hz, 1H), 4.57 (d, J = 10.8 Hz, 1H), 2.79 ‐2.72 (m, 1H), 1.96 ‐ 1.85 (m, 1H), 1.67 (s, 3H), 1.43 (s, 3H). 19F-NMR (376 MHz, CDCl3) δ -169.53 (s, 1F).そのクロマトグラフィー段階において、(3aR,4aR,6S,7aR,7bR)-7a-(ベンジルオキシ)-6-フルオロ-2,2-ジメチル-5-メチレンヘキサヒドロ-3aH-シクロペンタ[4,5]フロ[2,3-d][1,3]ジオキソールも得られた。1H-NMR (400 MHz, CDCl3) δ 7.45‐7.44 (m, 2H), 7.44‐7.27 (m, 3H), 5.87 (d, J = 3.6 Hz, 1H), 5.72 (dd, J = 4.4, 1.6 Hz, 2H), 5.58‐5.42 (m, 1H), 4.85 (s, 1H), 4.66 (dd, J = 17.2, 10.4 Hz, 2H), 4.61 (d, J = 4.0 Hz, 1H), 2.67‐2.56 (m, 1H), 2.02‐1.89 (m, 1H), 1.66 (s, 3H), 1.42 (s, 3H). 19F-NMR (376 MHz, CDCl3) δ -164.53 (s, 1F).
9F-NMR (376 MHz, クロロホルム-d) δ -137.96 (s, 1F), -182.37 (s, 1F).
段階1:(3aR,4aS,7aS,7bR)-7a-(ベンジルオキシ)-2,2-ジメチルヘキサヒドロ-5H-シクロペンタ[4,5]フロ[2,3-d][1,3]ジオキソール-5-オン(3.0g、9.9mmol)のトルエン(40mL)中混合物に、環境温度でアルゴン雰囲気下、トリエチルアミン(46.6mL、340mmol)を加えた。反応混合物を加熱して100℃とし、tert-ブチルジメチルシリルトリフルオロメタンスルホネート(5.21g、20.mmol)で処理した。得られた混合物を100℃で30分間攪拌した。反応完了後、混合物を冷却して室温とし、トルエン(300mL)で希釈し、飽和NaHCO3水溶液(300mL)で洗浄した。有機層を無水Na2SO4で脱水し、濾過した。濾液を減圧下に濃縮した。残留物をシリカでのカラムクロマトグラフィー(0%から15%EtOAc/石油エーテル)によって精製して、(((3aR,4aS,7aR,7bR)-7a-(ベンジルオキシ)-2,2-ジメチル-4a,7,7a,7b-テトラヒドロ-3aH-シクロペンタ[4,5]フロ[2,3-d][1,3]ジオキソール-5-イル)オキシ)(tert-ブチル)ジメチルシランを得た。1H-NMR (300 MHz, DMSO-d6) δ 7.36‐7.26 (m, 5H), 5.85 (d, J = 3.3 Hz, 1H), 4.81‐4.79 (m, 1H), 4.64‐4.56 (m, 3H), 4.46 (s, 1H), 2.70 - 2.64 (m, 1H), 2.37‐2.31 (m, 1H), 1.51 (s, 3H), 1.35 (s, 3H), 0.91 (s, 9H), 0.18 (s, 6H).
段階1:4-クロロ-5-ヨード-7H-ピロロ[2,3-d]ピリミジン(1.417g、5.07mmol)の脱水ACN(10mL)中溶液を、BSA(1.25mL、5.07mmol)とともに室温で15分間攪拌した。ACN(20mL)中の(3R,4R,5R)-5-((ベンジルオキシ)メチル)-4-メチルテトラヒドロフラン-2,3,4-トリイルトリアセテート(2g、5.07mmol)を加え、続いて、TMSOTf(1.84mL、10.1mmol)を加え、反応混合物を、室温でさらに10分間、続いて、80℃で3時間攪拌した。反応混合物を冷却して室温とし、EtOAc(40mL)で希釈した。反応混合物を飽和NaHCO3水溶液(30mLで2回)及びブライン(30mLで2回)で洗浄し、脱水した。残留物をシリカゲルでのカラムクロマトグラフィー(PE/Et2O)によって精製して、(2R,3R,4R,5R)-2-((ベンジルオキシ)メチル)-5-(4-クロロ-5-ヨード-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルテトラヒドロフラン-3,4-ジイルジアセテートを得た。MS:614(M+1)
段階1:DMF(16mL)に、カニューレを介して30分間かけて0℃でPOCl3(48.8mL、523mmol)を滴下し、反応混合物をこの温度でさらに30分間攪拌した。次に、N-(3-ブロモフェニル)アセトアミド(16g、75mmol)を混合物に加え、反応液を80℃で2時間攪拌した。溶媒を減圧下に除去して粗残留物を得て、それを飽和NaHCO3水溶液200mLで希釈し、EtOAc1000mLで抽出した。有機層を水(600mL)、ブライン(300mL)で洗浄し、無水硫酸ナトリウムで脱水し、濾過し、濾液を減圧下に濃縮した。得られた残留物をシリカゲルカラムクロマトグラフィー(20%EtOAc/PEで溶離)によって精製して、7-ブロモ-2-クロロキノリン-3-カルボアルデヒドを固体として得た。次に、7-ブロモ-2-クロロキノリン-3-カルボアルデヒド(1.8g、6.65mmol)をトルエン(5mL)と3回共留去した。7-ブロモ-2-クロロキノリン-3-カルボアルデヒド(1.8g、6.65mmol)のDCM(27mL)中溶液に0℃でDAST(1.76mL、13.31mmol)を加え、混合物を50℃で1.5時間攪拌した。反応液を0℃で飽和NaHCO3水溶液50mLによって希釈し、EtOAc250mLで抽出した。有機層を水(100mL)、ブライン(100mL)で洗浄し、無水硫酸ナトリウムで脱水し、濾過し、濾液を減圧下に濃縮した。得られた残留物をシリカゲルカラムクロマトグラフィー(30%DCM/PEで溶離)によって精製して、7-ブロモ-2-クロロ-3-(ジフルオロメチル)キノリンを固体として得た。MS:292/294(M+1/M+3)。
段階1:(3aR,4aR,6S,7aR,7bR)-7a-(ベンジルオキシ)-6-フルオロ-2,2-ジメチル-5-メチレンヘキサヒドロ-3aH-シクロペンタ[4,5]フロ[2,3-d][1,3]ジオキソール(190mg、0.593mmol)の無水THF(0.5mL)中溶液に、室温でアルゴン下に、9-BBN(7.12mL、0.5M THF中溶液、3.56mmol)を滴下した。混合物を70℃で1.5時間攪拌した。次に、混合物を冷却して0℃とし、K3PO4(755mg、3.56mmol)のH2O(2.5mL)中溶液を加えた。得られた混合物を室温でさらに0.5時間攪拌した。次に、7-ブロモ-3-フルオロキノリン-2-アミン(129mg、0.534mmol)の無水THF(3mL)中溶液及びPd(dppf)Cl2(43.4mg、0.059mmol)を混合物に加えた。最終反応混合物について、80℃で3時間にわたりマイクロ波照射を行った。有機層を分離し、水層をEtOAcで再抽出した(60mLで2回)。合わせた有機層をH2O(60mL)及びブライン(60mL)で洗浄し、無水Na2SO4で脱水し、濾過し、濾液を減圧下に濃縮した。得られた残留物をシリカゲルフラッシュクロマトグラフィー(0%から25%EtOAc/PEで溶離)によって精製して、7-(((3aR,4aR,5S,6S,7aR,7bR)-7a-(ベンジルオキシ)-6-フルオロ-2,2-ジメチルヘキサヒドロ-3aH-シクロペンタ[4,5]フロ[2,3-d][1,3]ジオキソール-5-イル)メチル)-3-フルオロキノリン-2-アミンを固体として得た。MS: 483 (M + 1). 1H-NMR (300 MHz, DMSO-d6) δ 7.81 (d, J = 11.7 Hz, 1H), 7.61 (d, J = 8.1 Hz, 1H), 7.47‐7.36 (m, 5H), 7.34‐7.29 (m, 1H), 7.15‐7.12 (m, 1H), 6.76 (br s, 2H), 5.86 (d, J = 3.9 Hz, 1H), 5.42 - 5.34 (m, 1H), 4.68‐4.65 (m, 2H), 4.57 (d, J = 11.1 Hz, 1H), 4.22 (s, 1H), 3.02 (dd, J = 14.1,
6.9 Hz, 1H), 2.86‐2.78 (m, 1H), 2.70 - 2.64 (m, 2H), 2.08‐1.90 (m, 1H), 1.40 (s, 3H), 1.30 (s, 3H).
段階1:3-アミノ-5-ブロモピコリンアルデヒド(1000mg、4.97mmol)をDMSO(10mL)に溶かし、2-フルオロアセトニトリル(1108μL、19.9mmol)、15M水酸化カリウム(100μL、1.49mmol)を入れ、80℃まで2時間加熱させた。反応液を水10mLに投入し、EtOAc(30mL)で希釈し、セライトで濾過した。有機層をブラインで洗浄し、硫酸ナトリウムで脱水し、濾過し、減圧下に濃縮した。残留物をシリカでのカラムクロマトグラフィー(0%から100%EtOAc/CH2Cl2)によって精製して、7-ブロモ-3-フルオロ-1,5-ナフチリジン-2-アミンを固体として得た。MS:242/244(M+1/3)。
段階1:2-アミノ-6-ブロモニコチンアルデヒド(2.6g、12.9mmol)及び鉄粉(7.22g、129mmol)の混合物を窒素下に脱気し、THF(26mL)を入れた。トリクロロアセトニトリル(1.95mL、19.4mmol)を加え、混合物を室温で2時間攪拌した。反応液を65℃で終夜還流させた。反応液を冷却して室温とし、セライトで濾過し、シリカゲル10gを入れた。混合物を減圧下に濃縮し、残留物をシリカでのカラムクロマトグラフィー(0%から50%の3:1EtOAc:EtOH/ヘキサン+1%NH4OH水溶液調整剤)によって精製した。得られた固体を冷Et2O 10mLで2回洗浄して、7-ブロモ-3-クロロ-1,8-ナフチリジン-2-アミンを固体として得て、それ以上精製せずに用いた。MS:258/260(M+1/3)。
段階1:4-メチル-7H-ピロロ[2,3-d]ピリミジン-2-アミン(0.5g、3.4mmol)のアセトニトリル(8.5mL)/DCM(8.5mL)中溶液に、ジ-tert-ブチルジカーボネート(2.6g、12mmol)及び4-ジメチルアミノピリジン(0.082g、0.68mmol)を加えた。溶液を室温で18時間攪拌した。反応液を濃縮し、シリカでのカラムクロマトグラフィー(0%から60%EtOAc/ヘキサン)によって精製して、tert-ブチル2-[ビス(tert-ブトキシカルボニル)アミノ]-4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-カルボキシレートを固体として得た。MS:449(M+1)。
アセトニトリル(11mL)中の2-クロロ-1H-ピロロ[2,3-d]ピリミジン(335mg、2.18mmol)に、Selectfluor(1.16g、3.27mmol)及びAcOH(1.1mL)を加えた。混合物を70℃で終夜加熱した。混合物を冷却して室温とし、減圧下に濃縮した。残留物をEtOAcで希釈し、水で洗浄した(2回)。溶液を硫酸ナトリウムで脱水し、濾過し、減圧下に濃縮した。残留物を、シリカでのクロマトグラフィー(20%から50%EtOAc/ヘキサン)によって精製して、2-クロロ-5-フルオロ-1H-ピロロ[2,3-d]ピリミジンを得た。MS:172(M+1)。
段階1:7H-ピロロ[2,3-d]ピリミジン-2-アミン(500mg、3.73mmol)のアセトニトリル(9mL)及びジクロロメタン(9mL)中の攪拌溶液に、Boc-無水物(2.85g、13.1mmol)及びDMAP(91mg、0.75mmol)を加えた。反応混合物を終夜攪拌した。混合物を減圧下に濃縮し、残留物をシリカでのカラムクロマトグラフィー(0%から40%EtOAc/ヘキサン)によって精製して、2-メチル-2-プロパニル2-(ビス{[(2-メチル-2-プロパニル)オキシ]カルボニル}アミノ)-7H-ピロロ[2,3-d]ピリミジン-7-カルボキシレートを得た。MS:435(M+1)。
段階1:4-(1,3-ジオキソイソインドリン-2-イル)ブタン酸(7.73g、33.1mmol)、HATU(15.1g、39.8mmol)及びDIEA(17.4mL、99mmol)のDMF(50mL)中溶液に、15℃で3-ブロモアニリン(5.7g、33.1mmol)を加えた。混合物を0.5時間攪拌した。水(500mL)を加え、混合物をEtOAcで抽出した(200mLで3回)。合わせた有機層をブライン(200mL)で洗浄し、減圧下に濃縮した。残留物を、EtOAcによる濾過によって精製して、N-(3-ブロモフェニル)-4-(1,3-ジオキソイソインドリン-2-イル)ブタンアミドを固体として得た。MS:387/389(M+1/M+3)。
段階1:ペンタ-4-イン-1-オール(2.4mL、25mmol)のDCM(200mL)中の溶液を入れたフラスコに、デス-マーチンペルヨージナン(14g、33mmol)を加えた。反応液を室温で終夜攪拌した。飽和重炭酸ナトリウム水溶液及び飽和チオ硫酸ナトリウム水溶液の両方の攪拌溶液が入ったビーカーに、反応液をゆっくり投入した。混合物を分液漏斗に投入し、抽出した。有機層を合わせ、硫酸マグネシウムで脱水し、セライト(登録商標)層で濾過し、減圧下に濃縮して、ペンタ-4-インアールを得て、それをそれ以上精製せずに次の段階で用いた。
下記の実験手順は、本開示の具体例の製造を詳細に説明するものである。当実施例は例示のみを目的とするものであり、いかなる形でも本開示の範囲を制限するものではない。
(1R,2S,3R,5R)-5-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-3-(4-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1-メチルシクロペンタン-1,2-ジオール
(1R,2S,3R,5R)-5-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1-メチルシクロペンタン-1,2-ジオール
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-エチニルテトラヒドロフラン-3,4-ジオール
(2R,3S,4R,5R)-2-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2,3-ジメチルテトラヒドロフラン-3,4-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルテトラヒドロフラン-3,4-ジオール(実施例10)、及び
(2R,3S,4R,5R)-2-{[(2-アミノ-3-ブロモキノリン-7-イル)オキシ]メチル}-5-(4-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルテトラヒドロフラン-3,4-ジオール(実施例11)
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-メトキシ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2-メチルテトラヒドロフラン-3,4-ジオール
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2-メチルテトラヒドロフラン-3,4-ジオール
(2R,3S,4R,5R)-2-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルテトラヒドロフラン-3,4-ジオール
(1S,2R,3S,5R)-3-[2-(2-アミノ-3-ブロモ-7-キノリニル)エチル]-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチル-1,2-シクロペンタンジオール
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール
(2R,3R,3aS,6S,6aR)-6-((6-アミノ-7-フルオロ-1,5-ナフチリジン-3-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール・3HCl
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-2-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(1S,2R,3R,5R)-3-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルシクロペンタン-1,2-ジオール
(1S,2R,3R,5R)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-(((2-アミノキノリン-7-イル)オキシ)メチル)-3-メチルシクロペンタン-1,2-ジオール
(1S,2R,5R)-3-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-(フルオロメチル)シクロペンタン-1,2-ジオール
1H).
(1R,2S,3R,5S)-5-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1-メチルシクロペンタン-1,2-ジオール
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-アミノキノリン-7-イル)オキシ)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
(1R,2S,3R,5R)-5-(((2-アミノ-3-メチルキノリン-7-イル)オキシ)メチル)-1-メチル-3-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
(1S,2R,3S,5R)-3-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-3-メチル-5-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール
(1R,2S,3R,5R)-5-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1,5-ジメチルシクロペンタン-1,2-ジオール
.49 - 2.41 (m, 1H), 2.22 - 2.14 (m, 1H), 1.34 (s, 3H), 0.79 (s, 9H), - 0.14 (s, 3H), - 0.38 (s, 3H).
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール及び(2R,3R,3aS,6S,6aR)-6-((2-アミノキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
(m, 1H), 2.08 - 1.97 (m, 3H).
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(2-アミノ-4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(ジフルオロメチル)キノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(1S,2R,3R,5R)-3-(2-(2-アミノ-3-フルオロキノリン-7-イル)エチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルシクロペンタン-1,2-ジオール
H), 1.88 - 1.73 (m, 2H), 1.46 (s, 3H), 1.25 (s, 3H), 1.21 (s, 3H).
(1R,2S,3R,5S)-5-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1,5-ジメチルシクロペンタン-1,2-ジオール
(1R,2S,3S,4R)-1-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-4-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2-メチルシクロペンタン-1,2,3-トリオール
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール2,2,2-トリフルオロアセテート
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)アミノ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6a-メチルヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(d, J = 6.0 Hz, 1H), 2.85 - 2.79 (m, 1H), 2.69 (s, 3H), 2.65 - 2.60 (m, 1H), 2.33 - 2.25 (m, 1H), 1.98 - 1.93 (m, 1H), 1.80 - 1.67 (m, 2H), 1.58 - 1.51 (m, 1H).
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-メチルキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(1S,2R,3S,5R)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-(2-(2,3-ジヒドロ-1H-ピロロ[2,3-b]キノリン-7-イル)エチル)-3-メチルシクロペンタン-1,2-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(2-アミノ-4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(ジフルオロメチル)キノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6R,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(2-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(2R,3R,3aS,6R,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール
(3aS,4S,5R)-1-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロ-1H-シクロペンタ[c]フラン-3a,4(3H)-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロフロ[3,4-b]フラン-3,3a(4H)-ジオール、及び
(2R,3R,3aS,6R,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロフロ[3,4-b]フラン-3,3a(4H)-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロフロ[3,4-b]フラン-3,3a(4H)-ジオール
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(ジフルオロメチル)キノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
PRMT5-MEP50生化学アッセイは、H4ヒストンのN末端由来の短ペプチド基質上の酵素複合体のメチル化活性の直接測定である。メチル化実験は、組換えPRMT5-MEP50タンパク質複合体を用いて行う。小分子の阻害効果の評価は、その化合物がこの反応を阻害する有効性によって測定される(EC50)。
PRMT5 TEアッセイは、PRMT5基質のアルギニンの対称ジメチル化(SDMA)を阻害する化合物を確認するためのバイオマーカーアッセイである。次の基質:ヒストンH2A及びH4 R3、ヒストンH3 R2、ヒストンH3 R8、スプライセオソームSmタンパク質、リボソームタンパク質RPS10、p53、FEN1、核質、ヌクレオリン、EGFR及びEBNAがPRMT5について報告されている。当該アッセイは、ハイコンテントイメージング技術を用いて対称ジメチル化核タンパク質を検出することに焦点を当てるものである。対称ジメチル化核タンパク質の発現の検出は、SDMA(CST13222)に対する一次ウサギモノクローナル抗体の混合物によるものであり、それは次に、Alexafluor 488色素結合抗ウサギIgG二次抗体によって認識される。IN Cell Analyzer 2200又はOpera-Phenixが、単一細胞レベルでの対称ジメチル化核タンパク質の発現レベルに直接関係する核Alexafluor 488蛍光色素強度を測定する。各化合物処理したウェルについての阻害パーセントを報告するため、核AF488色素強度を、DMSO処理細胞(MIN)についての平均値と比較する。
Claims (20)
- 下記式Iの化合物又は薬学的に許容されるその塩。
Xは、CH2又はOであり;
Yは、CH2、NH又はOであり;
Z1は、CR4又はNであり;
Z2、Z3、Z4、及びZ5は独立に、N及びCR9から選択され;
A1は、CH又はNであり;
A2は、CR10又はNであり;
A3は、CH又はNであり;
A4は、CR8又はNであり;
R1及びR7は、一緒になって、1~3個のハロゲンで置換されていても良い5員炭素環又は1個のO原子を含む5員複素環アルキル環を形成し;
R2は、H、OH、CH3、CHF2又はFであり;
R3は、H、ハロゲン、NH2、NHCH3、CN、OH、OCH3、1~3個のハロゲン若しくはOHで置換されていても良いC1-4アルキル、又は1~3個のハロゲン若しくはOHで置換されていても良いC3-5シクロアルキルであり;
R5は、H、NH2又はNHR6であり;そして、R4は、存在する場合、H、ハロゲン、CH3、CHF2、又はCF3であり;又は
R4及びR5が、それらが結合している炭素原子と一緒になって、1個のN原子を含む5員複素環アルキルを形成し、ここで、複素環アルキルは、ハロゲン、CH3、CF3、及びCF2Hから独立に選択される1~4個の置換基で置換されていても良く;
R6は、存在する場合、CH3、C2H5、CH2CH2CH3、CH(CH3)2、CH2CHF2、CH2CF3又はCH2-シクロプロピルであり;
R8は、存在する場合、H、ハロゲン、1~3個のハロゲンで置換されていても良いC1-4アルキル、1~3個のハロゲンで置換されていても良いC3-5シクロアルキル、又は1~3個のハロゲンで置換されていても良いアリールであり;
各R9は、存在する場合、H及びハロゲンから独立に選択され;そして
R10は、存在する場合、H、C1-6アルキル、NH2又はハロゲンである。] - 下記式(Ia)の化合物又は薬学的に許容されるその塩。
Xは、CH2又はOであり;
Yは、CH2、NH又はOであり;
Z1は、CR4又はNであり;
Z2は、CH又はNであり;
Z3は、CH又はNであり;
Z4は、CH又はNであり;
A1は、CH又はNであり;
A2は、CH、N、CNH2又はCCH3であり;
A3は、CH又はNであり;
A4は、CR8又はNであり;
R1及びR7 は一緒になって5員環を形成し;
R2は、H、OH、CH3、CHF2又はFであり;
R3は、H、ハロゲン、CH3、C2H5、シクロプロピル、NH2、NHCH3、CN、CF3、OH、OCH3又はCHF2であり;
R4は、存在する場合、H、ハロゲン、CH3、CHF2又はCF3であり;そして、
R5は、H、NH2又はNHR6であり;又は
R4及びR5が、それらが結合している炭素原子と一緒になって、1個のN原子を含む5員複素環アルキルを形成し、ここで、複素環アルキルは、ハロゲン、CH3、CF3、及びCF2Hから独立に選択される1~4個の置換基で置換されていても良く;
R6は、存在する場合、CH3、C2H5、CH2CH2CH3、CH(CH3)2、CH2CHF2、CH2CF3又はCH2-シクロプロピルであり;そして、
R8は、存在する場合、H、C1-4アルキル又はハロゲンである。] - 下記式Ibの請求項1に記載の化合物又は薬学的に許容されるその塩。
Xは、CH2又はOであり;
Yは、CH2、NH、又はOであり;
Wは、CR11R11又はOであり;
Z2、Z3、Z4及びZ5は、独立に、N及びCR9から選択され;
A2は、CR10又はNであり;
R2は、H、OH、CH3、CHF2又はFであり;
R3は、H、ハロゲン、OH、NH2、NHCH3、CN、OCH3、1~3個のハロゲン若しくはOHで置換されていても良いC1-4アルキル、又は1~3個のハロゲン若しくはOHで置換されていても良いC3-5シクロアルキルであり;
R4は、H、ハロゲン、CH3、CHF2又はCF3であり;
R5は、H、NH2、又はNHR6であり;
R8は、H、ハロゲン、1~3個のハロゲンで置換されていても良いC1-4アルキル、1~3個のハロゲンで置換されていても良いC3-5シクロアルキル、又は1~3個のハロゲンで置換されていても良いアリールであり;
各R9は、存在する場合、H及びハロゲンから独立に選択され;
R10は、存在する場合、H、C1-6アルキル、NH2、又はハロゲンであり;そして
各R11は、存在する場合、H及びハロゲンから独立に選択される。] - R4が、H、F、Cl、Br、CF3、CHF2又はCH3である、請求項3に記載の化合物又は薬学的に許容されるその塩。
- 各R9が、存在する場合、F、Cl及びHから独立に選択される、請求項3若しくは4に記載の化合物又は薬学的に許容されるその塩。
- A2が、N、CH、CNH2、CF、CCl又はC(CH3)である、請求項3、4若しくは5に記載の化合物又は薬学的に許容されるその塩。
- R3が、NH2、Cl、OCH3、CH2OH、CHF2、C(CH3)2OH、CH2CH3、CH(CH3)2、シクロプロピル、NHCH3又はCH3である、請求項3、4、5若しくは6に記載の化合物又は薬学的に許容されるその塩。
- R8が、H、CH3、CH2CH3、シクロプロピル、CHF2又はFである、
請求項3、4、5、6若しくは7に記載の化合物又は薬学的に許容されるその塩。 - R5が、NH2、NHCH2CF3又はNHCH2シクロプロピルである、請求項3、4、5、6、7若しくは8に記載の化合物又は薬学的に許容されるその塩。
- Wが、O、CHF、CF2又はCH2である、請求項3、4、5、6、7、8若しくは9に記載の化合物又は薬学的に許容されるその塩。
- 式Icの請求項1に記載の化合物又は薬学的に許容されるその塩。
Xは、CH2又はOであり;
Yは、CH2、NH又はOであり;
Wは、CH2又はOであり;
R2は、H、OH、CH3、CHF2 またはFであり;
R3は、H、ハロゲン、CH3、C2H5、シクロプロピル、NH2、NHCH3、CN、CF3、OH、OCH3又はCHF2、CH2OH、C(CH3)2OH、CH2CH3又はCH(CH3)2であり;
R4は、H、ハロゲン、CH3、CHF2又はCF3であり;
R5は、H、NH2又はNHR6であり;又は
R4及びR5が、それらが結合している炭素原子と一緒になって、1個のN原子を含む5員複素環アルキルを形成し、ここで、複素環アルキルは、ハロゲン、CH3、CF3 及びCF2Hから独立に選択される1~4個の置換基で置換されていても良く;
R6は、存在する場合、CH3、C2H5、CH2CH2CH3、CH(CH3)2、CH2CHF2、CH2CF3又はCH2-シクロプロピルであり;そして
R8は、H、C1-4アルキル又はハロゲンである。] - R2がHである、請求項11に記載の化合物又は薬学的に許容されるその塩。
- R3が、CH3、Cl、OCH3、CH2OH、C(CH3)2OH、CHF2、CH2CH3、CH(CH3)2、シクロプロピル又はNH2である、請求項11若しくは12に記載の化合物又は薬学的に許容されるその塩。
- R4が、H、Cl、F、CH3、CHF2、CF3又はBrである、請求項11、12若しくは13に記載の化合物又は薬学的に許容されるその塩。
- R5が、NH2、NHCH2CF3又はNHCH2シクロプロピルである、請求項11、12、13若しくは14に記載の化合物又は薬学的に許容されるその塩。
- R8がHである、請求項11、12、13、14若しくは15に記載の化合物又は薬学的に許容されるその塩。
- (2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4R,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3,8-ジフルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-クロロ-5-フルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-クロロ-8-フルオロキノリン-7-イル)メチル]-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(ジフルオロメチル)キノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3,5-ジフルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((6-アミノ-7-フルオロ-1,5-ナフチリジン-3-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロ-8-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3,6-ジフルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((7-アミノ-6-クロロ-1,8-ナフチリジン-2-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3,5-ジフルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(1S,2R,3aR,4S,6aR)-2-(4-アミノ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-4-((2-アミノ-3-クロロキノリン-7-イル)メチル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-2-(4-アミノ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-[(2-アミノ-3,5-ジフルオロキノリン-7-イル)メチル]-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-[(2-アミノ-3-クロロ-5-フルオロキノリン-7-イル)メチル]-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-2-(4-アミノ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-ブロモキノリン-7-イル)メチル]-2-[4-アミノ-5-(ジフルオロメチル)-7H-ピロロ[2,3-d]ピリミジン-7-イル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-2-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(2-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール二塩酸塩、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-2-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-[(2-アミノ-3-クロロキノリン-7-イル)メチル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-2-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-ブロモキノリン-7-イル)オキシ]-2-(4-アミノ-5-フェニル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-5-シクロプロピル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-[4-アミノ-5-(ジフルオロメチル)-7H-ピロロ[2,3-d]ピリミジン-7-イル]-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-ブロモキノリン-7-イル)オキシ]-2-(4-アミノ-5-シクロプロピル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-5,5-ジフルオロヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,5S,6S,6aR)-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-5-フルオロヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,5S,6S,6aR)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-[(2-アミノ-3-フルオロキノリン-7-イル)メチル]-5-フルオロヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-((2,2,2-トリフルオロエチル)アミノ)キノリン-7-イル)オキシ)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-((シクロプロピルメチル)アミノ)キノリン-7-イル)オキシ)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-2-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)オキシ)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)オキシ)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-5-エチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)オキシ)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)オキシ)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2,3-ジヒドロ-1H-ピロロ[2,3-b]キノリン-7-イル)オキシ)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(トリフルオロメチル)キノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-ブロモキノリン-7-イル)オキシ]-2-[4-(ヒドロキシメチル)-7H-ピロロ[2,3-d]ピリミジン-7-イル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-[(2-アミノ-3-ブロモキノリン-7-イル)オキシ]-2-[4-(2-ヒドロキシプロパン-2-イル)-7H-ピロロ[2,3-d]ピリミジン-7-イル]ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-(ジフルオロメチル)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(2,4-ジメチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(2,4-ジメチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-5-エチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-イソプロピル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(5-フルオロ-4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-シクロプロピル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(トリフルオロメチル)キノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2,3-ジヒドロ-1H-ピロロ[2,3-b]キノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(2,4-ジメチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(2,4-ジメチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(5-フルオロ-4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(2R,3R,3aS,6S,6aR)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6-((2-アミノキノリン-7-イル)オキシ)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(1R,2S,3R,5R)-5-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1,5-ジメチルシクロペンタン-1,2-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(2-アミノ-4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(ジフルオロメチル)キノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)アミノ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-6a-メチルヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-メチルキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(2-アミノ-4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(ジフルオロメチル)キノリン-7-イル)オキシ)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6R,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)オキシ)-2-(2-アミノ-5-フルオロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(2R,3R,3aS,6R,6aR)-6-((2-アミノ-3-クロロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-3aH-シクロペンタ[b]フラン-3,3a-ジオール、
(3aS,4S,5R)-1-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロ-1H-シクロペンタ[c]フラン-3a,4(3H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロフロ[3,4-b]フラン-3,3a(4H)-ジオール、
(2R,3R,3aS,6R,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロフロ[3,4-b]フラン-3,3a(4H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-5-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロフロ[3,4-b]フラン-3,3a(4H)-ジオール、
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-ブロモキノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)テトラヒドロフロ[3,4-b]フラン-3,3a(4H)-ジオール、又は
(2R,3R,3aS,6S,6aR)-6-((2-アミノ-3-(ジフルオロメチル)キノリン-7-イル)メチル)-2-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロ-2H-シクロペンタ[b]フラン-3,3a-ジオール
である請求項1に記載の化合物又は薬学的に許容されるその塩。 - 以下の化合物又は薬学的に許容されるその塩;
(1R,2S,3R,5R)-5-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-3-(4-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1-メチルシクロペンタン-1,2-ジオール、
(1R,2S,3R,5R)-5-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1-メチルシクロペンタン-1,2-ジオール、
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-エチニルテトラヒドロフラン-3,4-ジオール、
(2R,3S,4R,5R)-2-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2,3-ジメチルテトラヒドロフラン-3,4-ジオール、
(2R,3S,4R,5R)-2-{[(2-アミノ-3-ブロモキノリン-7-イル)オキシ]メチル}-5-(4-クロロ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルテトラヒドロフラン-3,4-ジオール、
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-メトキシ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2-メチルテトラヒドロフラン-3,4-ジオール、
(2R,3S,4R,5R)-2-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2-メチルテトラヒドロフラン-3,4-ジオール、
(1S,2R,3S,5R)-3-[2-(2-アミノ-3-ブロモ-7-キノリニル)エチル]-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチル-1,2-シクロペンタンジオール、
(1S,2R,3aR,4S,6aR)-4-((2-アミノ-3-フルオロキノリン-7-イル)メチル)-2-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)ヘキサヒドロペンタレン-1,6a(1H)-ジオール、
(1R,2S,3R,5R)-5-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-1-メチル-3-(4-(メチルアミノ)-7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール、
(2R,3S,4R,5R)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2-メチル-2-((キノリン-7-イルオキシ)メチル)テトラヒドロフラン-3,4-ジオール、
(1S,2R,3R,5R)-3-(((2-アミノ-3-ブロモキノリン-7-イル)オキシ)メチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルシクロペンタン-1,2-ジオール、
(1S,2R,3R,5R)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-(((2-アミノキノリン-7-イル)オキシ)メチル)-3-メチルシクロペンタン-1,2-ジオール、
(1S,2R,5R)-3-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-(フルオロメチル)シクロペンタン-1,2-ジオール、
(1R,2S,3R,5S)-5-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1-メチルシクロペンタン-1,2-ジオール、
(1R,2S,3R,5R)-5-(((2-アミノキノリン-7-イル)オキシ)メチル)-1-メチル-3-(7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール、
(1R,2S,3R,5R)-5-(((2-アミノ-3-メチルキノリン-7-イル)オキシ)メチル)-1-メチル-3-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール、
(1S,2R,3S,5R)-3-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-3-メチル-5-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール、
(1S,2R,3S,5R)-3-(2-(2,3-ジヒドロ-1H-ピロロ[2,3-b]キノリン-7-イル)エチル)-3-メチル-5-(4-メチル-7H-ピロロ[2,3-d]ピリミジン-7-イル)シクロペンタン-1,2-ジオール、
(1S,2R,3R,5R)-3-(2-(2-アミノ-3-フルオロキノリン-7-イル)エチル)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-メチルシクロペンタン-1,2-ジオール、
(1R,2S,3R,5S)-5-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-3-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-1,5-ジメチルシクロペンタン-1,2-ジオール、
(1R,2S,3S,4R)-1-(2-(2-アミノ-3-ブロモキノリン-7-イル)エチル)-4-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-2-メチルシクロペンタン-1,2,3-トリオール、
(1S,2R,3S,5R)-5-(4-アミノ-7H-ピロロ[2,3-d]ピリミジン-7-イル)-3-(2-(2,3-ジヒドロ-1H-ピロロ[2,3-b]キノリン-7-イル)エチル)-3-メチルシクロペンタン-1,2-ジオール。 - 請求項1~18のいずれか1項に記載の化合物又は薬学的に許容されるその塩、及び医薬担体を含む、がん治療のための組成物。
- がん治療用の医薬の製造における、請求項1~18のいずれか1項に記載の化合物又は薬学的に許容されるその塩の使用。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862715446P | 2018-08-07 | 2018-08-07 | |
US62/715,446 | 2018-08-07 | ||
US201962792623P | 2019-01-15 | 2019-01-15 | |
US62/792,623 | 2019-01-15 | ||
US201962859490P | 2019-06-10 | 2019-06-10 | |
US62/859,490 | 2019-06-10 | ||
PCT/US2019/045050 WO2020033288A1 (en) | 2018-08-07 | 2019-08-05 | Prmt5 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022501316A JP2022501316A (ja) | 2022-01-06 |
JP7446282B2 true JP7446282B2 (ja) | 2024-03-08 |
Family
ID=69414248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021506583A Active JP7446282B2 (ja) | 2018-08-07 | 2019-08-05 | Prmt5阻害剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220363707A1 (ja) |
EP (1) | EP3833355A4 (ja) |
JP (1) | JP7446282B2 (ja) |
KR (1) | KR20210046009A (ja) |
CN (1) | CN112805006A (ja) |
AU (1) | AU2019317549A1 (ja) |
BR (1) | BR112021002267A8 (ja) |
CA (1) | CA3108388A1 (ja) |
MA (1) | MA53287A (ja) |
MX (1) | MX2021001486A (ja) |
WO (1) | WO2020033288A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022512588A (ja) | 2018-10-05 | 2022-02-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | アルファ1アンチトリプシンのモジュレーター |
US11198699B2 (en) | 2019-04-02 | 2021-12-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
UY38696A (es) | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
AU2020283505A1 (en) * | 2019-05-30 | 2021-12-23 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as PRMT5 inhibitors |
CN115135651A (zh) | 2019-12-03 | 2022-09-30 | 鲁皮恩有限公司 | 作为prmt5抑制剂的被取代的核苷类似物 |
WO2021202480A1 (en) * | 2020-04-01 | 2021-10-07 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
US20230159504A1 (en) * | 2020-04-03 | 2023-05-25 | Vertex Pharmaceuticals Incorporated | 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd) |
WO2023001133A1 (zh) * | 2021-07-20 | 2023-01-26 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
WO2023017152A1 (en) | 2021-08-13 | 2023-02-16 | Albert-Ludwigs-Universität Freiburg | Specific small molecule inhibitors that block kmt9 methyltransferase activity and function |
CN116655638B (zh) * | 2022-05-12 | 2024-01-26 | 上海齐鲁制药研究中心有限公司 | 氘代prmt5抑制剂 |
WO2024032572A1 (zh) * | 2022-08-09 | 2024-02-15 | 上海湃隆生物科技有限公司 | 新型prmt5抑制剂及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017032840A1 (en) | 2015-08-26 | 2017-03-02 | Janssen Pharmaceutica Nv | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors |
WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
WO2019032859A1 (en) | 2017-08-09 | 2019-02-14 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2421879T3 (da) * | 2009-04-22 | 2013-11-25 | Acad Of Science Czech Republic | Nye 7-deazapurinnukleotider til terapeutiske anvendelser |
WO2012170347A1 (en) * | 2011-06-09 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
US20170198006A1 (en) * | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CN105837573B (zh) * | 2016-03-28 | 2018-07-27 | 江西青峰药业有限公司 | 一种9-[3a,6-二羟基六氢-1H-环戊二烯并[c]呋喃-4-基]鸟嘌呤的制备方法 |
-
2019
- 2019-08-05 MX MX2021001486A patent/MX2021001486A/es unknown
- 2019-08-05 EP EP19846885.2A patent/EP3833355A4/en active Pending
- 2019-08-05 BR BR112021002267A patent/BR112021002267A8/pt unknown
- 2019-08-05 JP JP2021506583A patent/JP7446282B2/ja active Active
- 2019-08-05 CN CN201980065660.9A patent/CN112805006A/zh active Pending
- 2019-08-05 US US17/266,521 patent/US20220363707A1/en active Pending
- 2019-08-05 CA CA3108388A patent/CA3108388A1/en active Pending
- 2019-08-05 MA MA053287A patent/MA53287A/fr unknown
- 2019-08-05 KR KR1020217006756A patent/KR20210046009A/ko active Search and Examination
- 2019-08-05 WO PCT/US2019/045050 patent/WO2020033288A1/en unknown
- 2019-08-05 AU AU2019317549A patent/AU2019317549A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017032840A1 (en) | 2015-08-26 | 2017-03-02 | Janssen Pharmaceutica Nv | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors |
WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
WO2019032859A1 (en) | 2017-08-09 | 2019-02-14 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
Non-Patent Citations (1)
Title |
---|
European Journal of Medicinal Chemistry,2018年07月29日,Vol. 157,pp. 248-267 |
Also Published As
Publication number | Publication date |
---|---|
KR20210046009A (ko) | 2021-04-27 |
EP3833355A1 (en) | 2021-06-16 |
BR112021002267A8 (pt) | 2023-02-07 |
JP2022501316A (ja) | 2022-01-06 |
AU2019317549A1 (en) | 2021-02-25 |
CN112805006A (zh) | 2021-05-14 |
EP3833355A4 (en) | 2022-05-11 |
MX2021001486A (es) | 2021-07-15 |
US20220363707A1 (en) | 2022-11-17 |
CA3108388A1 (en) | 2020-02-13 |
BR112021002267A2 (pt) | 2021-05-04 |
MA53287A (fr) | 2022-05-11 |
WO2020033288A1 (en) | 2020-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7446282B2 (ja) | Prmt5阻害剤 | |
JP6387013B2 (ja) | Hdm2阻害薬としての置換されたイミダゾピリジン類 | |
RU2660429C2 (ru) | Новые соединения, которые являются ингибиторами erk | |
EP2584903B1 (en) | Novel heterocyclic compounds as erk inhibitors | |
WO2012027239A1 (en) | NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | |
US20210309687A1 (en) | Prmt5 inhibitors | |
EP3706742B1 (en) | Prmt5 inhibitors | |
EP3833668A1 (en) | Prmt5 inhibitors | |
EP2953470B1 (en) | 2,6,7 substituted purines as hdm2 inhibitors | |
JP2023507634A (ja) | Prmt5阻害剤 | |
EP3833667B1 (en) | Prmt5 inhibitors | |
WO2023121939A1 (en) | Substituted benzothiophene derivatives and methods of use thereof | |
RU2814198C2 (ru) | Ингибиторы rmt5 | |
EP3233859B1 (en) | Bridged pyrazolopyridine derivatives as erk inhibitors useful for the treatement of cancer | |
JP2023508137A (ja) | Prmt5阻害剤 | |
EP2736338B1 (en) | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | |
US11981701B2 (en) | PRMT5 inhibitors | |
OA20817A (en) | PRMT5 inhibitors | |
EP4076460A1 (en) | Prmt5 inhibitors | |
WO2013016160A1 (en) | NOVEL IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS mTOR INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220613 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20220916 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230606 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240227 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7446282 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |